{"gene":"TCF21","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":2012,"finding":"Tcf21 (bHLH transcription factor) is required for lineage-specific epithelial-to-mesenchymal transition (EMT) of cardiac fibroblast progenitors in the epicardium; Tcf21-null hearts fail to form cardiac fibroblasts, and lineage-traced null cells are unable to undergo EMT, establishing Tcf21 as essential for cardiac fibroblast specification prior to EMT initiation.","method":"Tcf21-null mouse genetics, tamoxifen-inducible Cre lineage tracing, histological and immunofluorescence phenotyping","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotype, lineage tracing; replicated conceptually in multiple subsequent studies","pmids":["22573622"],"is_preprint":false},{"year":2012,"finding":"Pod1 (Tcf21) inhibits differentiation of epicardium-derived cells (EPDCs) into smooth muscle cells in the developing heart; loss of Pod1 results in increased smooth muscle marker expression on the heart surface and a paucity of interstitial fibroblasts, with epicardial EMT relatively unaffected; Pod1 expression in EPDCs is activated by retinoic acid signaling.","method":"Pod1 knockout mouse model, immunofluorescence for smooth muscle markers, retinoic acid treatment of isolated chick EPDCs, in vivo RA inhibition experiments","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in mouse with defined cellular phenotype plus pharmacological manipulation; independently consistent with cardiac fibroblast paper","pmids":["22687751"],"is_preprint":false},{"year":2013,"finding":"Tcf21 is required for proepicardial cell specification and formation of a mature epithelial epicardium in Xenopus; mass spectrometry of Tcf21 immunoprecipitates established its association with transcriptional co-repressor proteins, supporting a function for Tcf21 as a transcriptional repressor that controls proepicardial lineage determination.","method":"Tcf21 depletion in Xenopus (morpholino), mass spectrometry-based interactome, in vivo systems analysis of gene expression changes","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — MS-based co-IP identifying co-repressor interactions plus genetic depletion phenotype in a vertebrate model","pmids":["23637334"],"is_preprint":false},{"year":2014,"finding":"The lncRNA TARID activates TCF21 expression by inducing promoter demethylation: TARID physically interacts with both the TCF21 promoter and GADD45A, which then recruits thymine-DNA glycosylase for base-excision-repair-mediated demethylation; this involves TET-enzyme-mediated oxidation of 5-methylcytosine to 5-hydroxymethylcytosine at the TCF21 promoter.","method":"RNA immunoprecipitation, chromatin immunoprecipitation, bisulfite sequencing, base-excision repair assays, TET enzyme inhibition","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods (RIP, ChIP, bisulfite-seq, BER assay) in one rigorous study establishing the demethylation mechanism","pmids":["25087872"],"is_preprint":false},{"year":2006,"finding":"TCF21 is epigenetically silenced in lung and head and neck cancers by aberrant promoter methylation; exogenous expression of TCF21 in cells that have silenced endogenous TCF21 reduces tumor properties in vitro and in vivo, establishing a tumor suppressor function linked to its role in regulating mesenchymal-to-epithelial transition.","method":"Restriction landmark genomic scanning, methylation-specific PCR, exogenous TCF21 expression in cell lines, in vitro and xenograft tumor assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple methods (RLGS, MSP, functional rescue in vitro and in vivo); founding mechanistic study replicated widely","pmids":["16415157"],"is_preprint":false},{"year":2014,"finding":"A coronary heart disease–associated SNP (rs12190287) in the TCF21 3'-UTR disrupts an miR-224 binding site; the disease-associated C allele shows faster RNA–RNA complex formation and greater miR-224 binding compared with the protective G allele, leading to allele-specific reduction of TCF21 expression; miR-224 modulates TCF21 transcriptional response to TGF-β and PDGF signaling in an allele-specific manner.","method":"3'-UTR reporter gene assays in HCASMC, kinetic in vitro RNA-RNA binding assays, Pb2+/RNase T1 RNA probing, allelic imbalance analysis, miR-224 modulation experiments","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro biochemical RNA binding plus functional reporter assays plus allelic imbalance in patient tissue, multiple orthogonal methods","pmids":["24676100"],"is_preprint":false},{"year":2013,"finding":"The lead CHD-associated polymorphism rs12190287 disrupts an atypical AP-1 element in a TCF21 cis-regulatory enhancer, as demonstrated by allele-specific transcriptional regulation, transcription factor binding, and chromatin organization; this element also mediates signaling through PDGFR-β and WT1 pathways to regulate TCF21 expression.","method":"Luciferase reporter allele-specific assays, EMSA/TF binding assays, chromatin accessibility analysis, PDGFR-β and WT1 pathway perturbation experiments","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (reporter assay, TF binding, chromatin organization) in one study","pmids":["23874238"],"is_preprint":false},{"year":2015,"finding":"TCF21 promotes proliferation and migration and inhibits SMC lineage marker expression in human coronary artery SMC (HCASMC); vascular wall cells expressing Tcf21 migrate into atherosclerotic vascular lesions and contribute to the fibrous cap, where they activate SMC marker and growth factor receptor gene expression; RNA-Seq after siRNA knockdown identified downstream pathways related to vascular disease, cellular movement, and growth/proliferation.","method":"siRNA knockdown + RNA-Seq in HCASMC, in vitro proliferation/migration assays, reporter gene studies, immunolocalization, Cre-based lineage tracing in ApoE-/- and Ldlr-/- mice","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (RNA-Seq, in vitro functional assays, in vivo lineage tracing), two mouse models","pmids":["26020946"],"is_preprint":false},{"year":2019,"finding":"TCF21 antagonizes the MYOCD-SRF pathway to suppress SMC differentiation through multiple mechanisms: (1) TCF21 suppresses MYOCD and SRF at RNA and protein level; (2) ChIP-seq shows TCF21 binding colocalizes with SRF binding sites including at a novel SRF gene enhancer and MYOCD gene promoter; (3) TCF21 directly inhibits transcription at these sites via reporter assays; (4) TCF21 physically interacts with MYOCD (protein co-immunoprecipitation), blocking MYOCD-SRF association.","method":"ChIP-seq, siRNA/overexpression in HCASMC, luciferase reporter transfection assays, protein co-immunoprecipitation, in vitro genome editing of SRF CArG box, mouse in vivo mutation of orthologous enhancer","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (ChIP-seq, co-IP, reporter assay, genome editing in vitro and in vivo) in one rigorous study","pmids":["31815603"],"is_preprint":false},{"year":2019,"finding":"SMC-specific knockout of TCF21 in mice markedly inhibits SMC phenotypic modulation in atherosclerosis, leading to fewer fibromyocytes and fewer fibrous cap cells within lesions; single-cell RNA-seq established that modulated SMCs transform into fibroblast-like 'fibromyocytes' (not macrophages), and TCF21 expression strongly associates with this process in human coronary arteries.","method":"SMC-specific TCF21 knockout mouse, single-cell RNA sequencing of mouse and human atherosclerotic lesions, immunohistochemistry","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with defined phenotype plus human single-cell transcriptomic validation; high-impact replicated study","pmids":["31359001"],"is_preprint":false},{"year":2018,"finding":"TCF21 and SMAD3 promote opposing transcriptional programs in HCASMC: SMAD3 promotes SMC differentiation marker expression while inhibiting proliferation, opposing TCF21's pro-dedifferentiation activity; at colocalized DNA binding sites, SMAD3 and TCF21 binding are inversely correlated, with TCF21 locally blocking chromatin accessibility at SMAD3 binding sites; TCF21 directly inhibits SMAD3 activation of gene expression in reporter assays.","method":"RNA-Seq, ChIP-Seq for SMAD3 and TCF21 in HCASMC, chromatin accessibility (ATAC-seq), luciferase reporter transfection assays, siRNA knockdown","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP-seq, ATAC-seq, reporter assay, RNA-seq) in one study","pmids":["30307970"],"is_preprint":false},{"year":2015,"finding":"ChIP-seq in HCASMC identified the canonical TCF21 DNA binding sequence as CAGCTG; TCF21 binding sites significantly overlap AP-1 (JUN/JUND) binding loci in HCASMC; TCF21 target genes are enriched for processes including 'growth factor binding,' 'matrix interaction,' and 'smooth muscle contraction.'","method":"ChIP-seq with TCF21, JUN, and JUND antibodies in HCASMC; motif analysis; eQTL overlap analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq with multiple transcription factors; canonical motif independently confirmed in additional studies","pmids":["26020271"],"is_preprint":false},{"year":2011,"finding":"TCF21 binds the promoter of the melanoma metastasis-suppressing gene KISS1 and enhances its gene expression through interaction with E12 (TCF3 isoform) and TCF12; loss of TCF21 expression causes loss of KISS1 expression through loss of direct TCF21 occupancy at the KISS1 promoter; TCF21 overexpression inhibits motility of melanoma cells.","method":"Chromatin immunoprecipitation at KISS1 promoter, co-immunoprecipitation with E12/TCF12, siRNA knockdown, cell motility assays","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and co-IP establish direct binding and protein interaction; single lab, multiple methods","pmids":["21771727"],"is_preprint":false},{"year":2011,"finding":"SRY directly binds to the Tcf21 promoter at SRY/SOX9 response elements and activates TCF21 gene expression; mutagenesis of SRY/SOX9 response elements in the Tcf21 promoter eliminates SRY-driven activation; SRY was found to associate with the Tcf21 promoter in vivo during fetal rat testis development; TCF21 promotes in vitro sex reversal of embryonic ovarian cells to induce precursor Sertoli cell differentiation.","method":"Promoter reporter assays with mutagenesis, ChIP of SRY at Tcf21 promoter in fetal rat testis, embryonic ovarian cell culture sex-reversal assay, transcriptome analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reporter + mutagenesis + in vivo ChIP + functional sex-reversal assay; multiple orthogonal methods in one study","pmids":["21637323"],"is_preprint":false},{"year":2012,"finding":"ChIP-chip analysis identified 121 direct downstream TCF21 binding targets in Sertoli cells; one key bHLH target is scleraxis (Scx); SRY and TCF21 induce initial stages of Sertoli cell differentiation, while SCX induces later stages, establishing a cascade SRY→TCF21→SCX that promotes Sertoli cell fate.","method":"ChIP-chip comparative hybridization for TCF21 targets, embryonic ovarian gonadal cell culture sex-reversal assay with Sry, Tcf21, and Scx transfections, transferrin gene expression as Sertoli marker","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-chip genome-wide target identification plus functional differentiation assay; single lab","pmids":["23034159"],"is_preprint":false},{"year":2016,"finding":"TCF21 is sumoylated by SUMO1 at lysine residue K24; mutation of K24 to arginine completely abolishes sumoylation; sumoylation stabilizes TCF21 protein without affecting subcellular localization; sumoylation enhances TCF21 interaction with HDAC1/2 (without affecting TCF21-ERα interaction); sumoylated TCF21 shows enhanced recruitment of HDAC1/2 to the pS2 promoter and enhanced repression of ERα transcriptional activity; SENP1 reverses TCF21 sumoylation.","method":"Co-immunoprecipitation for SUMO1-TCF21 and HDAC1/2-TCF21, site-directed mutagenesis (K24R), protein half-life assay with SUMOylation inhibitor, subcellular localization assay, ChIP at pS2 promoter, luciferase reporter assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple co-IP and mutagenesis experiments; single lab with orthogonal methods","pmids":["27028856"],"is_preprint":false},{"year":2019,"finding":"TCF21 is required for visceral adipose stem cell (ASC)-specific expression of IL-6; TCF21 also promotes MMP-dependent collagen degradation and type IV collagen deposition through regulation of MMP2, MMP13, TIMP1, and COL4A1 in visceral ASCs; the MMP2 and COL4A1 regulatory effects are IL-6-independent.","method":"siRNA-mediated Tcf21 knockdown and lentiviral TCF21 overexpression in mouse ASCs, qRT-PCR, ELISA for IL-6, zymography for MMP activity, collagen assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function experiments with multiple downstream readouts; single lab","pmids":["29540474"],"is_preprint":false},{"year":2015,"finding":"POD-1/TCF21 overexpression reduces SHP mRNA and protein levels by binding to E-box sequences in the SHP promoter (demonstrated by ChIP), indirectly affecting LRH-1 regulation and increasing Cyclin E1 expression; this is mechanistically distinct from TCF21's regulation of SF-1.","method":"ChIP assay at SHP promoter, qRT-PCR, Western blot for SHP, LRH-1, and Cyclin E1 in hepatocarcinoma and adrenocortical tumor cells with POD-1 overexpression","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus protein expression analysis; single lab, multiple cell types","pmids":["26421305"],"is_preprint":false},{"year":2015,"finding":"POD-1/TCF21 overexpression significantly decreases endogenous SF-1 mRNA and protein in adrenal fasciculata/reticularis (F/R) cells, and also decreases the SF-1 target StAR; this effect is cell-zone-specific (not observed in glomerulosa cells), corroborating direct TCF21-mediated repression of SF-1 in normal adrenocortical cells.","method":"Primary culture of rat adrenal G and F/R cells, pCMVMycPod-1 transfection, qRT-PCR, Western blot for SF-1, StAR, CYP11B2","journal":"Brazilian journal of medical and biological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with multiple downstream molecular readouts; single lab","pmids":["26421867"],"is_preprint":false},{"year":2019,"finding":"TCF21 directly promotes LPL gene transcription by binding to the E-box motif in the LPL promoter, as demonstrated by ChIP and luciferase assays; TCF21 knockdown and overexpression attenuate and promote preadipocyte differentiation respectively, with changes in C/EBPα, LPL, and A-FABP expression.","method":"Chromatin immunoprecipitation assay, luciferase reporter assay, siRNA knockdown, TCF21 overexpression in chicken preadipocytes, lipid droplet accumulation quantification","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase assay establish direct binding at LPL promoter; single lab","pmids":["31065241"],"is_preprint":false},{"year":2021,"finding":"SUMOylation of TCF21 is increased in endometriotic tissues and is enhanced by estrogen; SUMOylation stabilizes TCF21 protein (shown by protein half-life assay with ginkgolic acid) and increases its interaction with USF2 (co-immunoprecipitation); SUMOylated TCF21 shows increased binding activity of USF2 to the SF-1 and ERβ promoters; TCF21/USF2 heterodimer binds to SF-1 and ERβ promoters to activate their expression.","method":"Co-immunoprecipitation, protein half-life assay with SUMOylation inhibitor, ChIP at SF-1 and ERβ promoters, estrogen treatment experiments in endometriotic stromal cells","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, half-life assay, and ChIP are orthogonal; single lab","pmids":["33693540"],"is_preprint":false},{"year":2022,"finding":"ChIP-seq in adrenocortical carcinoma NCI-H295R cells overexpressing TCF21 identified CACNA1B (encoding N-type calcium channel Cav2.2) as a direct TCF21 target; TCF21 negatively regulates CACNA1B/Cav2.2 expression, suggesting a mechanism of steroidogenesis control in addition to SF-1 inhibition.","method":"ChIP-seq in NCI-H295R cells overexpressing TCF21, validation by qRT-PCR and Western blot for CACNA1B","journal":"Neoplasma","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with validation; single lab","pmids":["35603952"],"is_preprint":false},{"year":2025,"finding":"Tcf21 directly binds gene loci including COL1A1, COL3A1, IL6, and PDGFRB (by ChIP-seq); Tcf21 promotes cardiac fibroblast activation and fibrosis through upregulation of extracellular matrix genes and the Pdgfrb-Erk pathway; Tcf21-knockout fibroblasts show severely suppressed Pdgfrb-Erk signaling; inducible Tcf21 KO mice are resistant to cardiac fibrosis induced by isoproterenol or metabolic overload.","method":"ChIP-seq in Tcf21-knockout vs WT cardiac fibroblasts, in vitro fibroblast culture from KO embryos, inducible Tcf21 KO mouse models (isoproterenol and streptozotocin/HFD), gene expression analysis","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq, multiple KO mouse models with disease phenotype, in vitro mechanistic confirmation; single lab but orthogonal methods","pmids":["40753125"],"is_preprint":false},{"year":2019,"finding":"TCF21 inhibits anti-angiogenic activity in cholangiocarcinoma by targeting PI3K/Akt and ERK1/2 signaling; ectopic TCF21 expression in CCA cells reduces VEGFA and PDGF-BB expression/secretion (shown by immunohistochemistry and ELISA) and conditioned medium from TCF21-overexpressing cells reduces endothelial cell viability, migration, and tube formation; PI3K/Akt and ERK1/2 pathway inhibition mediates these effects.","method":"Lentiviral TCF21 overexpression in CCA cell lines, conditioned medium endothelial cell assays (viability, migration, tube formation), xenograft growth, immunohistochemistry, ELISA for VEGFA/PDGF-BB, Western blot for signaling pathway proteins","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro functional assays with molecular readouts; single lab, multiple methods","pmids":["30920845"],"is_preprint":false},{"year":2018,"finding":"TCF21 interacts with p53 signaling as a transcriptional target of p53 in response to hypoxia in uterine endometrial carcinoma cells; TCF21 interferes with the MAPK pathway by reducing phosphorylated ERK1 (MAPK1), and a specific domain of TCF21 responsible for interaction with MEK was identified by molecular docking and mutagenesis.","method":"TCF21 overexpression in UCEC cells, hypoxia treatment of wild-type vs p53-deficient cells, molecular docking and mutagenesis of TCF21 domain, Western blot for phospho-ERK, in vitro proliferation and invasion assays, in vivo xenograft","journal":"DNA and cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mutagenesis identified binding domain but molecular docking is computational; interaction with MEK not confirmed by co-IP; single lab","pmids":["29608330"],"is_preprint":false},{"year":2020,"finding":"TCF21 overexpression in FAP-high cancer-associated fibroblasts (CAFs) in ovarian cancer decreases their ability to promote invasion, chemoresistance, and in vivo tumor growth, acting as a master regulator of CAF state; TCF21 is specifically expressed in FAP-low CAFs.","method":"TCF21 overexpression in FAP-high CAFs, co-culture invasion assays, in vivo tumor growth assays, flow cytometry for CD49e/FAP markers","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional overexpression with in vitro and in vivo readouts; single lab","pmids":["32434219"],"is_preprint":false},{"year":2019,"finding":"TCF21 lineage cells constitute the lung lipofibroblast population; after E15.5, Tcf21 progenitor cells exclusively become lipofibroblasts and interstitial fibroblasts; overexpression of Tcf21 in primary neonatal lung fibroblasts increases intracellular neutral lipids, suggesting Tcf21 regulates lipofibroblast function.","method":"Tcf21 inducible Cre lineage tracing at multiple embryonic time points, lipid staining (neutral lipid quantification), Tcf21 overexpression in neonatal lung fibroblasts","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lineage tracing plus functional overexpression with lipid readout; single lab","pmids":["30675802"],"is_preprint":false},{"year":2023,"finding":"DNMT3a binds the TCF21 promoter resulting in TCF21 hypermethylation in hepatic stellate cells (HSCs); TCF21 downstream binding protein hnRNPA1 inhibits the NF-κB signaling pathway to accelerate hepatic fibrosis reversal; the DNMT3a-TCF21-hnRNPA1 axis regulates HSC activation.","method":"ChIP for DNMT3a at TCF21 promoter, bisulfite sequencing, co-immunoprecipitation for TCF21-hnRNPA1 interaction, NF-κB pathway inhibition assays in HSCs","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and co-IP establish molecular interactions; single lab, multiple orthogonal methods","pmids":["37268177"],"is_preprint":false},{"year":2023,"finding":"TCF21 loss in epicardium-derived cells causes increased myofibroblast differentiation, whereas TCF21 overexpression suppresses TGF-β signaling and myofibroblast differentiation; lncRNA-TARID (enriched in mesenchymal stem cell EVs) upregulates Tcf21 expression in epicardium-derived cells, and TARID-laden lipid nanoparticles improve cardiac function in mouse and porcine myocardial infarction models.","method":"Gain- and loss-of-function experiments in epicardium-derived cells, TGF-β signaling pathway analysis (Western blot), intrapericardial EV injection in mouse MI model, lipid nanoparticle delivery of lncRNA-TARID in mouse and porcine MI models","journal":"European heart journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss/gain-of-function with molecular pathway readout, in vivo models in two species; single lab","pmids":["36916305"],"is_preprint":false},{"year":2021,"finding":"Tcf21 inhibits adipogenesis at least partially by accentuating Dlk1 expression; loss of Tcf21 in visceral adipose Tcf21 lineage cells (Tcf21 LCs) promotes adipogenesis and developmental progress, leading to improved metabolic health in diet-induced obesity; multiomics (scRNA-seq + chromatin accessibility) defined the gene-regulatory network governing Tcf21 LC activities.","method":"Tcf21 conditional knockout mice, scRNA-seq, ATAC-seq, gene-regulatory network analysis, metabolic phenotyping under HFD","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with multiomics and functional metabolic readout; single lab","pmids":["36857185"],"is_preprint":false},{"year":2021,"finding":"ChIP-seq in parietal epithelial cells (PECs) transfected with Tcf21-GFP identified a genome-wide Tcf21 binding site consensus as CAGCTG (E-box motif CANNTG); Tcf21 expression in PECs downregulates PEC-specific markers (caveolin-1, β-catenin, Pax2) and the transcription factor YY1; co-expression of YY1 with Tcf21 rescues Tcf21-induced multinucleation/budding/micronuclei and tetraploidy; Tcf21 target genes include cell cycle regulators (Mdm2, Cdc45, Cyclin D1, Cyclin D2) and microtubule stability genes.","method":"ChIP-seq in Tcf21-GFP-transfected PECs, motif analysis, qRT-PCR and Western blot for target genes/proteins, co-expression rescue experiments, flow cytometry for ploidy","journal":"Cellular physiology and biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with functional validation of binding motif and target genes; single lab","pmids":["34148307"],"is_preprint":false},{"year":2020,"finding":"TCF21 directly interacts with HHIP protein (co-immunoprecipitation); inhibition of TCF21 or HHIP individually promotes liver cancer cell proliferation and metastasis; knockdown of TCF21 or HHIP counteracts the protective effects of miR-25-3p inhibitor on cell proliferation and metastasis.","method":"Co-immunoprecipitation for TCF21-HHIP interaction, luciferase reporter for miR-25-3p targeting, siRNA knockdown of TCF21/HHIP, CCK-8/transwell/wound-healing assays, xenograft","journal":"Cell proliferation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP for TCF21-HHIP interaction; functional consequence not fully dissected from TCF21 alone","pmids":["32525231"],"is_preprint":false},{"year":2024,"finding":"TCF21 directly binds the ABCA10 promoter (confirmed by dual-luciferase reporter and ChIP assay) to activate ABCA10 expression; TCF21 overexpression increases ABCA10-mediated mitochondrial cholesterol efflux in DDP-resistant ovarian cancer cells, sensitizing them to cisplatin; knockdown of ABCA10 reverses TCF21's ability to enhance cisplatin sensitivity.","method":"Dual-luciferase reporter assay, ChIP assay for TCF21 at ABCA10 promoter, lentiviral ABCA10 overexpression/knockdown and TCF21 overexpression in DDP-resistant OV cell lines, mitochondrial cholesterol measurement, cholesterol efflux assay, apoptosis assay","journal":"Biochemical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay establish direct binding; functional rescue with multiple molecular readouts; single lab","pmids":["39438390"],"is_preprint":false},{"year":2024,"finding":"TCF21 directly activates PDE4C expression by binding to its promoter (confirmed by ChIP-seq and dual-luciferase reporter assay); TCF21 overexpression in endometrial stromal cells suppresses intracellular cAMP levels by upregulating PDE4C and also suppresses FOXO1 expression, thereby impairing decidualization.","method":"RNA-seq after TCF21 overexpression in HESCs, ChIP-seq and ChIP-qPCR for TCF21 at PDE4C promoter, dual-luciferase reporter assay, cAMP ELISA, FOXO1/decidual marker qRT-PCR/Western blot","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and reporter assay confirm direct TCF21-PDE4C binding; single lab with multiple orthogonal methods","pmids":["39326465"],"is_preprint":false},{"year":2025,"finding":"TCF21 transcriptionally represses ERO1A expression (confirmed by dual-luciferase/ChIP assay); TCF21-mediated ERO1A repression reduces IDO1 expression and PD-L1 levels, thereby limiting immune evasion in lung adenocarcinoma cells; TCF21 overexpression inhibits LUAD cell migration/invasion and enhances CD8+ T cell cytotoxicity.","method":"Dual-luciferase assay and ChIP for TCF21-ERO1A binding, gene knockdown/overexpression experiments, Seahorse metabolic analysis, flow cytometry for CD8+ T cell activation, transwell migration/invasion assays, LUAD mouse models","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay establish direct binding; functional rescue experiments; single lab","pmids":["40659157"],"is_preprint":false},{"year":2026,"finding":"TCF21 directly activates LIMK2 transcription (ChIP-seq and epigenomic data in patient-derived ectopic stromal cells); TCF21-activated LIMK2-cofilin signaling promotes actin-cytoskeleton reorganization, increased cell invasion and adhesion in endometriotic stromal cells; uterine-specific Tcf21 knockout in mice dysregulates EMT of endometrium; TCF21 overexpression via AAV-Pgr-Tcf21 increases endometriosis incidence in mice, which is mitigated by LIMK inhibitor LIMKi 3.","method":"ChIP-seq in patient-derived ectopic stromal cells, uterine-specific Tcf21 conditional KO mice, AAV-Pgr-Tcf21 mouse model, LIMK inhibitor treatment, actin cytoskeleton imaging, invasion/adhesion assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq, multiple in vivo mouse models (KO and OE), pharmacological rescue, and functional cellular assays; single lab but orthogonal methods","pmids":["41786705"],"is_preprint":false},{"year":2021,"finding":"TCF21 directly promotes chicken preadipocyte differentiation by binding to the E-box motif in the HTR2A promoter (genome-wide ChIP-seq, ChIP-qPCR, and luciferase reporter assay); pharmacological activation or inhibition of HTR2A respectively promotes or attenuates preadipocyte differentiation; HTR2A inhibition impairs TCF21-promoted adipogenesis.","method":"ChIP-seq and RNA-seq in chicken differentiated preadipocytes, ChIP-qPCR and luciferase reporter validation of HTR2A as direct target, pharmacological HTR2A modulation, oil red-O staining","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq + reporter assay establish direct binding; functional rescue with pharmacology; single lab","pmids":["34872001"],"is_preprint":false},{"year":2025,"finding":"Loss of Tcf21 in cardiac fibroblasts causes increased myofibroblast-like gene expression and differentiation; AAV-mediated cardiac fibroblast-specific TCF21 overexpression in vivo exerts an anti-fibrotic effect and improves cardiac remodelling in a mouse model; snRNA-seq identified a disease-specific fibroblast subpopulation in human aortic stenosis where TCF21 is a key regulator.","method":"snRNA-seq of human fibrotic and non-failing hearts, cardiac fibroblast-specific AAV-knockdown and AAV-overexpression in vivo in mice, in vitro cardiac fibroblast loss/gain-of-function, immunohistochemistry","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo AAV-based KD and OE with cardiac phenotype plus human snRNA-seq validation; multiple orthogonal approaches","pmids":["41926244"],"is_preprint":false},{"year":2022,"finding":"TCF21 in tumor pericytes increases perivascular ECM stiffness, collagen rearrangement, and basement membrane degradation; loss of integrin α5 in TCF21-high pericytes inhibits the FAK/PI3K/AKT/DNMT1 axis to impair TCF21 DNA hypermethylation; pericyte-conditional Tcf21 knockout mitigates perivascular ECM remodelling and colorectal cancer liver metastasis.","method":"scRNA-seq, pericyte-conditional Tcf21 KO mice (CRC model), ChIP-seq and bisulfite-seq, atomic force microscopy for ECM stiffness, second-harmonic generation microscopy, integrin α5 pathway inhibition studies","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO mice plus ChIP-seq and pathway inhibition; single lab but multiple orthogonal methods","pmids":["36805487"],"is_preprint":false},{"year":2017,"finding":"TCF21 (Tcf21) directly regulates the Slug promoter by occupying E-box sequences; Tcf21-Slug balance defines distinct migratory modalities (proliferative/passive cooperative cell migration, active CCM, and EMT) in high-grade serous ovarian cancer cells; phenotypic transitions following drug exposure ensue from occupancy of Slug promoter E-boxes by Tcf21.","method":"ChIP at Slug promoter E-boxes, gene manipulation (overexpression/knockdown) of Tcf21 and Slug, live imaging of cell migration, flow cytometry","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP at target promoter plus functional gene manipulation with live imaging; single lab","pmids":["31241128"],"is_preprint":false},{"year":2024,"finding":"Tcf21 is required for specification of Foxd1+ stromal progenitors to the juxtaglomerular (JG) cell lineage during early kidney development (E12); Tcf21 inactivation in Foxd1+ cells (but not in Ren1+ cells) results in fewer renin-positive areas and altered renal arterial morphology; pseudotime trajectory analysis shows Tcf21 expression is highest in early metanephric mesenchyme and declines as cells mature into renin-expressing JG cells.","method":"Foxd1;Tcf21 conditional KO and Ren1;Tcf21 conditional KO mouse models, immunostaining, in situ hybridization, scRNA-seq, scATAC-seq, pseudotime trajectory analysis","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in two cell-type-specific models with multiomics (scRNA-seq + scATAC-seq) plus histological validation; peer-reviewed with preprint version also available","pmids":["39589156"],"is_preprint":false},{"year":2024,"finding":"Loss of Tcf21 in Foxd1+ stromal progenitors results in depletion of multiple stromal subpopulations (medullary/perivascular, collecting duct-associated, proliferating, and nephrogenic zone-associated stroma) and emergence of a novel Emcn-expressing stromal population with profibrotic transcriptional programs; Tcf21 loss leads to architectural disruption, interstitial fibrosis, and impaired renal function in adult mice.","method":"scRNA-seq on E14.5 Foxd1-lineage cells from Tcf21-cKO and control kidneys, scATAC-seq, immunostaining, bulk RNA-seq at E18.5, histological analysis at 2 months","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with scRNA-seq, scATAC-seq and longitudinal histology; multiple orthogonal approaches","pmids":["41632505"],"is_preprint":false},{"year":2025,"finding":"Loss of tcf21 in zebrafish epicardial cells reduces the presence of dedifferentiated cardiomyocytes in the injury area and impairs heart regeneration, establishing that epicardial Tcf21 is required for cardiomyocyte dedifferentiation during cardiac regeneration.","method":"Conditional tcf21 flox allele with 4-OHT-inducible CreERT2 in adult zebrafish, ventricular resection heart injury model, quantification of dedifferentiated cardiomyocytes, histological assessment of regeneration","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional genetic deletion in zebrafish with defined regeneration phenotype; single lab","pmids":["41360282"],"is_preprint":false},{"year":2017,"finding":"TCF21 regulates miR-224-mediated allelic imbalance at rs12190287 in HCASMC: higher TCF21 expression is anti-correlated with miR-224 levels, and miR-224 modulates TCF21 transcriptional response to TGF-β and PDGF in an allele-specific manner, indicating bimodal regulatory complexity at this CAD locus (previously also shown: rs12190287 disrupts AP-1 binding; see PMID 23874238).","method":"miR-224 and TCF21 expression correlation in HCASMC; miR-224 overexpression and inhibition experiments with TGF-β/PDGF treatment, allele-specific reporter assays","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional experiments in primary HCASMC with allele-specific readouts; single lab, builds on prior AP-1 study","pmids":["24676100"],"is_preprint":false}],"current_model":"TCF21 is a class II bHLH transcription factor that binds E-box sequences (canonical CAGCTG) in target gene promoters/enhancers to act primarily as a transcriptional repressor of smooth muscle cell (SMC) differentiation—by directly interacting with and blocking the MYOCD-SRF pathway and by opposing SMAD3 activity—while promoting SMC phenotypic modulation toward a fibroblast-like state during atherosclerosis; it is essential for cardiac fibroblast specification from epicardial progenitors (requiring EMT), for Foxd1+ kidney stromal progenitor fate determination, and for Sertoli cell differentiation downstream of SRY; its activity is post-translationally regulated by SUMO1-mediated sumoylation (at K24, reversed by SENP1) which stabilizes the protein and enhances HDAC1/2 recruitment; its expression is epigenetically controlled by promoter methylation/demethylation (via the TARID lncRNA–GADD45A–TET–BER pathway) and post-transcriptionally by miR-224 (allele-specifically at rs12190287); in cancer contexts TCF21 functions as a tumor suppressor by activating KISS1, repressing PI3K/AKT and ERK signaling, promoting mesenchymal-to-epithelial reversion, and directly activating ABCA10-mediated mitochondrial cholesterol efflux, while in cardiac and endometrial fibrosis it directly binds and regulates ECM gene loci (COL1A1, COL3A1) and activates LIMK2-cofilin signaling to drive cytoskeletal reorganization."},"narrative":{"mechanistic_narrative":"TCF21 is a class II basic helix-loop-helix transcription factor that controls mesenchymal cell-fate determination, fibroblast specification, and phenotypic plasticity across cardiovascular, renal, gonadal, and tumor contexts, binding the canonical E-box CAGCTG and frequently overlapping AP-1 (JUN/JUND) loci in target enhancers [PMID:26020271, PMID:34148307]. In the developing heart it is essential for specifying cardiac fibroblast progenitors and their epithelial-to-mesenchymal transition from the epicardium, while restraining differentiation of epicardium-derived cells toward smooth muscle [PMID:22573622, PMID:22687751]. In vascular smooth muscle, TCF21 drives phenotypic modulation toward a fibroblast-like 'fibromyocyte' state that populates the atherosclerotic fibrous cap, acting as a transcriptional repressor of the SMC differentiation program: it suppresses and physically binds MYOCD to block MYOCD-SRF complex formation, and it antagonizes SMAD3 by locally restricting chromatin accessibility at shared binding sites [PMID:26020946, PMID:31815603, PMID:31359001, PMID:30307970]. Beyond the vasculature, TCF21 acts downstream of SRY through SRY/SOX9 promoter elements to initiate Sertoli cell differentiation via a SRY→TCF21→SCX cascade [PMID:21637323, PMID:23034159], and is required for specification of Foxd1+ renal stromal progenitors, whose loss causes stromal depletion, emergence of profibrotic populations, and interstitial fibrosis [PMID:39589156, PMID:41632505]. TCF21 expression is set epigenetically: the lncRNA TARID recruits GADD45A and the TET/base-excision-repair machinery to demethylate the TCF21 promoter [PMID:25087872], a circuit silenced by aberrant promoter methylation in cancer where TCF21 acts as a tumor suppressor [PMID:16415157]. A coronary-disease-associated polymorphism (rs12190287) tunes TCF21 levels through both disruption of an enhancer AP-1 element and allele-specific miR-224 binding in its 3'-UTR [PMID:24676100, PMID:23874238]. TCF21 protein is stabilized and rendered a more potent repressor by SUMO1 sumoylation at K24, which enhances HDAC1/2 recruitment and is reversed by SENP1 [PMID:27028856]. Its direct transcriptional outputs are context-specific, including activation of the metastasis suppressor KISS1 [PMID:21771727], repression of MYOCD/SRF and SMAD3 targets in SMCs [PMID:31815603, PMID:30307970], direct regulation of ECM and PDGFRB-ERK genes (COL1A1, COL3A1, PDGFRB) driving cardiac fibroblast activation [PMID:40753125, PMID:41926244], and activation of LIMK2-cofilin signaling promoting cytoskeletal reorganization and invasion in endometriosis [PMID:41786705].","teleology":[{"year":2006,"claim":"Established TCF21 as a tumor suppressor silenced by promoter methylation, defining the first disease-relevant mechanism and linking its loss to mesenchymal-to-epithelial transition control.","evidence":"Restriction landmark genomic scanning, methylation-specific PCR, and functional rescue in cell lines and xenografts in lung and head/neck cancer","pmids":["16415157"],"confidence":"High","gaps":["Did not identify direct transcriptional targets mediating suppression","Mechanism of MET reversion not defined at the gene level"]},{"year":2011,"claim":"Identified TCF21 as a direct activator of the metastasis suppressor KISS1 and a partner of E12/TCF12, providing an early molecular handle on its tumor-suppressive transcriptional output.","evidence":"ChIP at KISS1 promoter, co-IP with E12/TCF12, and motility assays in melanoma cells","pmids":["21771727"],"confidence":"Medium","gaps":["Single lab","Whether KISS1 activation generalizes beyond melanoma not established"]},{"year":2011,"claim":"Placed TCF21 downstream of SRY in male sex determination, showing SRY directly activates the Tcf21 promoter to drive Sertoli cell differentiation.","evidence":"Promoter reporter mutagenesis, in vivo ChIP of SRY in fetal rat testis, and ovarian cell sex-reversal assays","pmids":["21637323"],"confidence":"High","gaps":["TCF21 direct targets in Sertoli cells not yet mapped at this stage"]},{"year":2012,"claim":"Defined TCF21 as essential for cardiac fibroblast specification and EMT from epicardial progenitors while restraining SMC differentiation, establishing its developmental fibroblast-fate role.","evidence":"Tcf21-null and Pod1 knockout mouse genetics, lineage tracing, and retinoic acid manipulation","pmids":["22573622","22687751"],"confidence":"High","gaps":["Direct transcriptional targets in epicardial EMT not identified","Co-repressor partners not yet defined"]},{"year":2012,"claim":"Mapped genome-wide TCF21 targets in Sertoli cells and defined a SRY→TCF21→SCX differentiation cascade, extending the gonadal program downstream.","evidence":"ChIP-chip target identification and Sry/Tcf21/Scx sex-reversal transfection assays","pmids":["23034159"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect target distinction limited by ChIP-chip resolution"]},{"year":2013,"claim":"Provided biochemical evidence that TCF21 functions as a transcriptional repressor by associating with co-repressor complexes during proepicardial lineage determination.","evidence":"Mass-spectrometry interactome of Tcf21 immunoprecipitates plus morpholino depletion in Xenopus","pmids":["23637334"],"confidence":"High","gaps":["Specific co-repressor subunits and target loci not resolved"]},{"year":2013,"claim":"Connected the coronary-disease GWAS signal to TCF21 regulation, showing rs12190287 disrupts an enhancer AP-1 element controlling allele-specific expression downstream of PDGFR-β and WT1.","evidence":"Allele-specific luciferase reporters, TF-binding/EMSA, chromatin accessibility, and pathway perturbation in vascular cells","pmids":["23874238"],"confidence":"High","gaps":["Causal in vivo demonstration of the variant effect on disease not established"]},{"year":2014,"claim":"Defined the TARID lncRNA–GADD45A–TET–base-excision-repair circuit that activates TCF21 by promoter demethylation, explaining how TCF21 silencing is reversed.","evidence":"RIP, ChIP, bisulfite-seq, BER assays, and TET inhibition in one integrated study","pmids":["25087872"],"confidence":"High","gaps":["Upstream signals controlling TARID expression not defined"]},{"year":2014,"claim":"Established a second, post-transcriptional layer of the CAD locus: rs12190287 alters a 3'-UTR miR-224 site, tuning TCF21 response to TGF-β and PDGF allele-specifically.","evidence":"3'-UTR reporters, kinetic RNA-RNA binding assays, RNA probing, and allelic imbalance in HCASMC","pmids":["24676100","23874238"],"confidence":"High","gaps":["Relative contribution of enhancer vs 3'-UTR mechanisms to disease risk not quantified"]},{"year":2015,"claim":"Defined the canonical TCF21 DNA-binding motif (CAGCTG) genome-wide and showed extensive co-binding with AP-1, framing how TCF21 engages SMC enhancers.","evidence":"ChIP-seq with TCF21/JUN/JUND antibodies and motif/eQTL analysis in HCASMC","pmids":["26020271"],"confidence":"High","gaps":["Whether AP-1 co-binding is cooperative or antagonistic not resolved here"]},{"year":2015,"claim":"Demonstrated functionally that TCF21 promotes SMC proliferation/migration, suppresses SMC markers, and contributes vascular cells to the atherosclerotic fibrous cap.","evidence":"siRNA-RNA-Seq, in vitro functional assays, and lineage tracing in ApoE-/- and Ldlr-/- mice","pmids":["26020946"],"confidence":"High","gaps":["Direct repression mechanism of SMC genes not yet defined at this stage"]},{"year":2015,"claim":"Extended TCF21 repressor function to steroidogenic and metabolic loci, showing E-box-dependent repression of SHP and SF-1.","evidence":"ChIP at SHP promoter and gain-of-function expression analysis in adrenocortical and hepatocarcinoma cells","pmids":["26421305","26421867"],"confidence":"Medium","gaps":["Single lab","Direct vs indirect SF-1 repression not fully separated"]},{"year":2016,"claim":"Identified SUMO1 sumoylation at K24 (reversed by SENP1) as a post-translational switch that stabilizes TCF21 and enhances HDAC1/2-dependent repression.","evidence":"Co-IP, K24R mutagenesis, half-life and ChIP/reporter assays at the pS2 promoter","pmids":["27028856"],"confidence":"Medium","gaps":["Single lab","SUMO ligase and physiological signals triggering sumoylation not identified"]},{"year":2017,"claim":"Showed TCF21 directly controls EMT/migration modality via E-box occupancy at the Slug promoter, linking it to cancer cell phenotypic transitions.","evidence":"ChIP at Slug E-boxes with gene manipulation and live migration imaging in ovarian cancer cells","pmids":["31241128"],"confidence":"Medium","gaps":["Single lab","Whether Slug regulation is activating or repressive context-dependent"]},{"year":2018,"claim":"Resolved the TCF21–SMAD3 antagonism in SMCs, showing TCF21 locally blocks chromatin accessibility at SMAD3 sites to oppose SMC differentiation.","evidence":"ChIP-seq, ATAC-seq, RNA-seq and reporter assays in HCASMC","pmids":["30307970"],"confidence":"High","gaps":["Mechanism by which TCF21 reduces accessibility not biochemically defined"]},{"year":2019,"claim":"Established the central mechanism of SMC phenotypic modulation: TCF21 antagonizes MYOCD-SRF transcriptionally and by physically binding MYOCD, and SMC-specific deletion blocks fibromyocyte formation in atherosclerosis.","evidence":"ChIP-seq, co-IP, reporter and genome editing assays plus SMC-specific KO and single-cell RNA-seq of mouse and human lesions","pmids":["31815603","31359001"],"confidence":"High","gaps":["Whether fibromyocyte fate is protective or detrimental in human disease not resolved"]},{"year":2019,"claim":"Broadened TCF21 function into adipose/lung mesenchymal and fibrotic biology, regulating IL-6, MMP/collagen genes, LPL, and lipofibroblast identity.","evidence":"Loss/gain-of-function with qRT-PCR, zymography, ChIP/luciferase, and lineage tracing in adipose, lung, and preadipocyte models","pmids":["29540474","30675802","31065241"],"confidence":"Medium","gaps":["Single labs per tissue","Cross-tissue conservation of these targets unclear"]},{"year":2019,"claim":"Showed TCF21 suppresses pro-angiogenic and pro-survival signaling (VEGFA/PDGF-BB, PI3K/Akt, ERK1/2) consistent with its tumor-suppressor role.","evidence":"Ectopic expression, conditioned-medium endothelial assays, and signaling Westerns in cholangiocarcinoma","pmids":["30920845"],"confidence":"Medium","gaps":["Single lab","Direct transcriptional targets mediating signaling suppression not identified"]},{"year":2021,"claim":"Defined TCF21 as a master regulator of fibroblast/pericyte/stromal cell states across cancer and metabolic contexts, including CAF state, adipogenesis via Dlk1/HTR2A, and parietal epithelial cell ploidy via YY1.","evidence":"Overexpression and conditional KO with multiomics (scRNA-seq, ATAC-seq), ChIP-seq, and functional rescue across ovarian CAF, adipose, and renal PEC systems","pmids":["32434219","36857185","34148307","34872001"],"confidence":"Medium","gaps":["Context-specific direct targets only partially overlapping","Single labs per system"]},{"year":2021,"claim":"Revealed that sumoylation-dependent TCF21–USF2 heterodimers can act as activators (of SF-1 and ER-β) in estrogen-driven endometriosis, showing TCF21 can switch from repressor to activator depending on partner.","evidence":"Co-IP, half-life and ChIP assays at SF-1/ER-β promoters in endometriotic stromal cells","pmids":["33693540"],"confidence":"Medium","gaps":["Single lab","Determinants selecting repressor vs activator complexes unclear"]},{"year":2023,"claim":"Extended TCF21 regulation and function to fibrosis-relevant tissues, including DNMT3a-mediated promoter methylation in hepatic stellate cells and suppression of TGF-β-driven myofibroblast differentiation rescued by TARID delivery.","evidence":"ChIP, bisulfite-seq, co-IP (hnRNPA1) in HSCs and gain/loss-of-function with EV/lipid-nanoparticle TARID delivery in mouse and porcine MI models","pmids":["37268177","36916305"],"confidence":"Medium","gaps":["Single labs","Whether TARID therapy effects are fully TCF21-dependent not isolated"]},{"year":2024,"claim":"Identified additional direct TCF21 targets linking it to cholesterol efflux, decidualization, renal progenitor specification, and tumor immune evasion.","evidence":"ChIP/ChIP-seq and reporter assays (ABCA10, PDE4C, ERO1A) plus conditional KO with multiomics in kidney (Foxd1 lineage)","pmids":["39438390","39326465","39589156","40659157"],"confidence":"Medium","gaps":["Each target validated in a single context","Generality of cholesterol/immune outputs unknown"]},{"year":2025,"claim":"Established TCF21 as a direct, context-determinant regulator of fibrosis: it activates ECM/PDGFRB-ERK and LIMK2-cofilin programs to drive fibrosis in some tissues while restraining myofibroblast conversion in others, with in vivo anti-fibrotic effects of cardiac TCF21 overexpression.","evidence":"ChIP-seq, multiple inducible/conditional KO and AAV overexpression mouse models, pharmacological LIMK inhibition, and human snRNA-seq","pmids":["40753125","41786705","41926244","41360282","41632505"],"confidence":"High","gaps":["Why TCF21 is pro-fibrotic in some fibroblasts but anti-fibrotic in others is unresolved","Direct chromatin determinants of the opposite outcomes not defined"]},{"year":null,"claim":"How TCF21 selects between transcriptional repression (MYOCD/SRF, SMAD3, ERO1A) and activation (KISS1, ABCA10, LIMK2) at distinct loci, and what cofactor/PTM context dictates pro- versus anti-fibrotic outcomes, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model of repressor-vs-activator switching","Structural basis of partner selection (E12/TCF12, USF2, MYOCD, HDAC1/2) not determined","Determinants of tissue-specific fibrosis outcome unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,8,10,11,12,13,22,30,32,33,34,35]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[11,30,8,32,33]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8,11,15,30]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[8,10,11,13,22,30,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,13,40,41]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,9,7,22,35]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[16,22,38]}],"complexes":[],"partners":["MYOCD","SMAD3","HDAC1","HDAC2","USF2","TCF12","SUMO1","HNRNPA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O43680","full_name":"Transcription factor 21","aliases":["Capsulin","Class A basic helix-loop-helix protein 23","bHLHa23","Epicardin","Podocyte-expressed 1","Pod-1"],"length_aa":179,"mass_kda":19.7,"function":"Involved in epithelial-mesenchymal interactions in kidney and lung morphogenesis that include epithelial differentiation and branching morphogenesis. May play a role in the specification or differentiation of one or more subsets of epicardial cell types","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O43680/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TCF21","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TCF21","total_profiled":1310},"omim":[{"mim_id":"616058","title":"TCF21 ANTISENSE RNA INDUCING PROMOTER DEMETHYLATION; TARID","url":"https://www.omim.org/entry/616058"},{"mim_id":"605362","title":"CARDIOMYOPATHY, DILATED, 1J; CMD1J","url":"https://www.omim.org/entry/605362"},{"mim_id":"603628","title":"MUSCULIN; MSC","url":"https://www.omim.org/entry/603628"},{"mim_id":"603306","title":"TRANSCRIPTION FACTOR 21; TCF21","url":"https://www.omim.org/entry/603306"},{"mim_id":"602054","title":"T-BOX TRANSCRIPTION FACTOR 1; TBX1","url":"https://www.omim.org/entry/602054"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":197.6},{"tissue":"ovary","ntpm":192.4}],"url":"https://www.proteinatlas.org/search/TCF21"},"hgnc":{"alias_symbol":["POD1","bHLHa23"],"prev_symbol":[]},"alphafold":{"accession":"O43680","domains":[{"cath_id":"4.10.280","chopping":"79-155","consensus_level":"medium","plddt":84.5213,"start":79,"end":155}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43680","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43680-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43680-F1-predicted_aligned_error_v6.png","plddt_mean":66.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TCF21","jax_strain_url":"https://www.jax.org/strain/search?query=TCF21"},"sequence":{"accession":"O43680","fasta_url":"https://rest.uniprot.org/uniprotkb/O43680.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43680/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43680"}},"corpus_meta":[{"pmid":"31359001","id":"PMC_31359001","title":"Atheroprotective roles of smooth muscle cell phenotypic modulation and the TCF21 disease gene as revealed by single-cell analysis.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31359001","citation_count":667,"is_preprint":false},{"pmid":"22573622","id":"PMC_22573622","title":"The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22573622","citation_count":391,"is_preprint":false},{"pmid":"21653610","id":"PMC_21653610","title":"tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21653610","citation_count":246,"is_preprint":false},{"pmid":"25087872","id":"PMC_25087872","title":"Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25087872","citation_count":235,"is_preprint":false},{"pmid":"30176158","id":"PMC_30176158","title":"CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression.","date":"2018","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/30176158","citation_count":163,"is_preprint":false},{"pmid":"21432986","id":"PMC_21432986","title":"Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney.","date":"2011","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/21432986","citation_count":138,"is_preprint":false},{"pmid":"16415157","id":"PMC_16415157","title":"Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16415157","citation_count":137,"is_preprint":false},{"pmid":"22687751","id":"PMC_22687751","title":"Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22687751","citation_count":109,"is_preprint":false},{"pmid":"24676100","id":"PMC_24676100","title":"Coronary heart disease-associated variation in TCF21 disrupts a miR-224 binding site and miRNA-mediated regulation.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24676100","citation_count":95,"is_preprint":false},{"pmid":"21847011","id":"PMC_21847011","title":"TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.","date":"2011","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21847011","citation_count":94,"is_preprint":false},{"pmid":"26020946","id":"PMC_26020946","title":"Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26020946","citation_count":88,"is_preprint":false},{"pmid":"31815603","id":"PMC_31815603","title":"Coronary Disease-Associated Gene TCF21 Inhibits Smooth Muscle Cell Differentiation by Blocking the Myocardin-Serum Response Factor Pathway.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/31815603","citation_count":84,"is_preprint":false},{"pmid":"23637334","id":"PMC_23637334","title":"Tcf21 regulates the specification and maturation of proepicardial cells.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23637334","citation_count":78,"is_preprint":false},{"pmid":"32434219","id":"PMC_32434219","title":"Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32434219","citation_count":69,"is_preprint":false},{"pmid":"36805487","id":"PMC_36805487","title":"Novel TCF21high pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix.","date":"2022","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/36805487","citation_count":67,"is_preprint":false},{"pmid":"30675802","id":"PMC_30675802","title":"The Tcf21 lineage constitutes the lung lipofibroblast population.","date":"2019","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30675802","citation_count":62,"is_preprint":false},{"pmid":"23874238","id":"PMC_23874238","title":"Disease-related growth factor and embryonic signaling pathways modulate an enhancer of TCF21 expression at the 6q23.2 coronary heart disease locus.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23874238","citation_count":62,"is_preprint":false},{"pmid":"33985545","id":"PMC_33985545","title":"CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33985545","citation_count":60,"is_preprint":false},{"pmid":"20945327","id":"PMC_20945327","title":"Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers.","date":"2010","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20945327","citation_count":60,"is_preprint":false},{"pmid":"36916305","id":"PMC_36916305","title":"Intrapericardial long non-coding RNA-Tcf21 antisense RNA inducing demethylation administration promotes cardiac repair.","date":"2023","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/36916305","citation_count":59,"is_preprint":false},{"pmid":"21771727","id":"PMC_21771727","title":"Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21771727","citation_count":59,"is_preprint":false},{"pmid":"31662443","id":"PMC_31662443","title":"CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31662443","citation_count":52,"is_preprint":false},{"pmid":"28476165","id":"PMC_28476165","title":"MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer.","date":"2017","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/28476165","citation_count":52,"is_preprint":false},{"pmid":"30307970","id":"PMC_30307970","title":"Coronary artery disease genes SMAD3 and TCF21 promote opposing interactive genetic programs that regulate smooth muscle cell differentiation and disease risk.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30307970","citation_count":52,"is_preprint":false},{"pmid":"23206776","id":"PMC_23206776","title":"miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer.","date":"2012","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/23206776","citation_count":51,"is_preprint":false},{"pmid":"27894084","id":"PMC_27894084","title":"Curcumin increases exosomal TCF21 thus suppressing exosome-induced lung cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27894084","citation_count":47,"is_preprint":false},{"pmid":"34162856","id":"PMC_34162856","title":"TCF21+ mesenchymal cells contribute to testis somatic cell development, homeostasis, and regeneration in mice.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34162856","citation_count":43,"is_preprint":false},{"pmid":"32542449","id":"PMC_32542449","title":"TCF21: a critical transcription factor in health and cancer.","date":"2020","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/32542449","citation_count":42,"is_preprint":false},{"pmid":"26158413","id":"PMC_26158413","title":"TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26158413","citation_count":40,"is_preprint":false},{"pmid":"26020271","id":"PMC_26020271","title":"Characterization of TCF21 Downstream Target Regions Identifies a Transcriptional Network Linking Multiple Independent Coronary Artery Disease Loci.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26020271","citation_count":40,"is_preprint":false},{"pmid":"18398044","id":"PMC_18398044","title":"Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay.","date":"2008","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18398044","citation_count":36,"is_preprint":false},{"pmid":"21637323","id":"PMC_21637323","title":"Basic helix-loop-helix transcription factor TCF21 is a downstream target of the male sex determining gene SRY.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21637323","citation_count":34,"is_preprint":false},{"pmid":"26435499","id":"PMC_26435499","title":"Down-regulation of TCF21 by hypermethylation induces cell proliferation, migration and invasion in colorectal cancer.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26435499","citation_count":30,"is_preprint":false},{"pmid":"28352192","id":"PMC_28352192","title":"TCF21 functions as a tumor suppressor in colorectal cancer through inactivation of PI3K/AKT signaling.","date":"2017","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28352192","citation_count":30,"is_preprint":false},{"pmid":"31071528","id":"PMC_31071528","title":"MicroRNA-3648 Is Upregulated to Suppress TCF21, Resulting in Promotion of Invasion and Metastasis of Human Bladder Cancer.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31071528","citation_count":29,"is_preprint":false},{"pmid":"29086202","id":"PMC_29086202","title":"Promoter methylation of TCF21 may repress autophagy in the progression of lung cancer.","date":"2017","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29086202","citation_count":28,"is_preprint":false},{"pmid":"23034159","id":"PMC_23034159","title":"SRY induced TCF21 genome-wide targets and cascade of bHLH factors during Sertoli cell differentiation and male sex determination in rats.","date":"2012","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23034159","citation_count":26,"is_preprint":false},{"pmid":"29540474","id":"PMC_29540474","title":"Transcription factor 21 (TCF21) promotes proinflammatory interleukin 6 expression and extracellular matrix remodeling in visceral adipose stem cells.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29540474","citation_count":25,"is_preprint":false},{"pmid":"29038558","id":"PMC_29038558","title":"Prokineticin receptor-1-dependent paracrine and autocrine pathways control cardiac tcf21+ fibroblast progenitor cell transformation into adipocytes and vascular cells.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29038558","citation_count":25,"is_preprint":false},{"pmid":"26390289","id":"PMC_26390289","title":"Regional differences in WT-1 and Tcf21 expression during ventricular development: implications for myocardial compaction.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26390289","citation_count":24,"is_preprint":false},{"pmid":"26044559","id":"PMC_26044559","title":"Clinicopathological significance and biological role of TCF21 mRNA in breast cancer.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26044559","citation_count":24,"is_preprint":false},{"pmid":"30662806","id":"PMC_30662806","title":"LncRNA LINC00163 upregulation suppresses lung cancer development though transcriptionally increasing TCF21 expression.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30662806","citation_count":24,"is_preprint":false},{"pmid":"32513244","id":"PMC_32513244","title":"Molecular mechanisms of coronary disease revealed using quantitative trait loci for TCF21 binding, chromatin accessibility, and chromosomal looping.","date":"2020","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/32513244","citation_count":24,"is_preprint":false},{"pmid":"31354385","id":"PMC_31354385","title":"MicroRNA-30-3p Suppresses Inflammatory Factor-Induced Endothelial Cell Injury by Targeting TCF21.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31354385","citation_count":23,"is_preprint":false},{"pmid":"32525231","id":"PMC_32525231","title":"Exosomes secreted by chronic hepatitis B patients with PNALT and liver inflammation grade ≥ A2 promoted the progression of liver cancer by transferring miR-25-3p to inhibit the co-expression of TCF21 and HHIP.","date":"2020","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/32525231","citation_count":22,"is_preprint":false},{"pmid":"29080283","id":"PMC_29080283","title":"TCF21 hypermethylation regulates renal tumor cell clonogenic proliferation and migration.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29080283","citation_count":19,"is_preprint":false},{"pmid":"30920845","id":"PMC_30920845","title":"TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.","date":"2019","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30920845","citation_count":19,"is_preprint":false},{"pmid":"31241128","id":"PMC_31241128","title":"Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31241128","citation_count":18,"is_preprint":false},{"pmid":"27270650","id":"PMC_27270650","title":"TCF21 genetic polymorphisms and breast cancer risk in Chinese women.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27270650","citation_count":18,"is_preprint":false},{"pmid":"22792366","id":"PMC_22792366","title":"A new Cre driver mouse line, Tcf21/Pod1-Cre, targets metanephric mesenchyme.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22792366","citation_count":18,"is_preprint":false},{"pmid":"31065241","id":"PMC_31065241","title":"A Novel Regulator of Preadipocyte Differentiation, Transcription Factor TCF21, Functions Partially Through Promoting LPL Expression.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31065241","citation_count":18,"is_preprint":false},{"pmid":"28235410","id":"PMC_28235410","title":"TCF21 is related to testis growth and development in broiler chickens.","date":"2017","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/28235410","citation_count":17,"is_preprint":false},{"pmid":"27028856","id":"PMC_27028856","title":"Sumoylation of TCF21 downregulates the transcriptional activity of estrogen receptor-alpha.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27028856","citation_count":17,"is_preprint":false},{"pmid":"27446425","id":"PMC_27446425","title":"Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27446425","citation_count":16,"is_preprint":false},{"pmid":"28663539","id":"PMC_28663539","title":"Transcription Factor 21 (TCF21) rs12190287 Polymorphism is Associated with Osteosarcoma Risk and Outcomes in East Chinese Population.","date":"2017","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/28663539","citation_count":16,"is_preprint":false},{"pmid":"37765264","id":"PMC_37765264","title":"Mechanism of TCF21 Downregulation Leading to Immunosuppression of Tumor-Associated Macrophages in Non-Small Cell Lung Cancer.","date":"2023","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/37765264","citation_count":14,"is_preprint":false},{"pmid":"29909422","id":"PMC_29909422","title":"Expression of Transcription Factor 21 (TCF21) and Upregulation Its Level Inhibits Invasion and Metastasis in Esophageal Squamous Cell Carcinoma.","date":"2018","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/29909422","citation_count":14,"is_preprint":false},{"pmid":"29608330","id":"PMC_29608330","title":"A Novel Target of p53, TCF21, Can Respond to Hypoxia by MAPK Pathway Inactivation in Uterine Corpus Endometrial Carcinoma.","date":"2018","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29608330","citation_count":14,"is_preprint":false},{"pmid":"33729392","id":"PMC_33729392","title":"Role of the bHLH transcription factor TCF21 in development and tumorigenesis.","date":"2021","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/33729392","citation_count":12,"is_preprint":false},{"pmid":"26090325","id":"PMC_26090325","title":"Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells that Contribute to the Fibrous Cap.","date":"2015","source":"Genomics data","url":"https://pubmed.ncbi.nlm.nih.gov/26090325","citation_count":11,"is_preprint":false},{"pmid":"36857185","id":"PMC_36857185","title":"Tcf21 marks visceral adipose mesenchymal progenitors and functions as a rate-limiting factor during visceral adipose tissue development.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36857185","citation_count":10,"is_preprint":false},{"pmid":"34424910","id":"PMC_34424910","title":"TCF21 regulates miR-10a-5p/LIN28B signaling to block the proliferation and invasion of melanoma cells.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34424910","citation_count":10,"is_preprint":false},{"pmid":"37268177","id":"PMC_37268177","title":"DNMT3a-mediated methylation of TCF21/hnRNPA1 aggravates hepatic fibrosis by regulating the NF-κB signaling pathway.","date":"2023","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/37268177","citation_count":10,"is_preprint":false},{"pmid":"26421305","id":"PMC_26421305","title":"POD-1/TCF21 Reduces SHP Expression, Affecting LRH-1 Regulation and Cell Cycle Balance in Adrenocortical and Hepatocarcinoma Tumor Cells.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26421305","citation_count":10,"is_preprint":false},{"pmid":"30296564","id":"PMC_30296564","title":"TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30296564","citation_count":9,"is_preprint":false},{"pmid":"26421867","id":"PMC_26421867","title":"POD-1/Tcf21 overexpression reduces endogenous SF-1 and StAR expression in rat adrenal cells.","date":"2015","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/26421867","citation_count":8,"is_preprint":false},{"pmid":"35071232","id":"PMC_35071232","title":"Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35071232","citation_count":8,"is_preprint":false},{"pmid":"30804710","id":"PMC_30804710","title":"Role of microRNA-92a in metastasis of osteosarcoma cells in vivo and in vitro by inhibiting expression of TCF21 with the transmission of bone marrow derived mesenchymal stem cells.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/30804710","citation_count":8,"is_preprint":false},{"pmid":"32122956","id":"PMC_32122956","title":"TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32122956","citation_count":7,"is_preprint":false},{"pmid":"34872001","id":"PMC_34872001","title":"Genome-wide survey and functional analysis reveal TCF21 promotes chicken preadipocyte differentiation by directly upregulating HTR2A.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34872001","citation_count":6,"is_preprint":false},{"pmid":"33693540","id":"PMC_33693540","title":"Increased SUMOylation of TCF21 improves its stability and function in human endometriotic stromal cells†.","date":"2021","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/33693540","citation_count":6,"is_preprint":false},{"pmid":"35601004","id":"PMC_35601004","title":"Association Between TCF21 Gene Polymorphism with the Incidence of Paroxysmal Atrial Fibrillation and the Efficacy of Radiofrequency Ablation for Patients with Paroxysmal Atrial Fibrillation.","date":"2022","source":"International journal of general medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35601004","citation_count":6,"is_preprint":false},{"pmid":"35910838","id":"PMC_35910838","title":"Delivery of miR-654-5p via SonoVue Microbubble Ultrasound Inhibits Proliferation, Migration, and Invasion of Vascular Smooth Muscle Cells and Arterial Thrombosis and Stenosis through Targeting TCF21.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35910838","citation_count":6,"is_preprint":false},{"pmid":"36943591","id":"PMC_36943591","title":"Tcf21 Alleviates Pancreatic Fibrosis by Regulating the Epithelial-Mesenchymal Transformation of Pancreatic Stellate Cells.","date":"2023","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36943591","citation_count":5,"is_preprint":false},{"pmid":"30615266","id":"PMC_30615266","title":"Dysregulation of ß-catenin, WISP1 and TCF21 predicts disease-specific survival and primary response against radio(chemo)therapy in patients with locally advanced squamous cell carcinomas of the head and neck.","date":"2019","source":"Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/30615266","citation_count":5,"is_preprint":false},{"pmid":"31312357","id":"PMC_31312357","title":"Promoter methylation of the candidate tumor suppressor gene TCF21 in myelodysplastic syndrome and acute myeloid leukemia.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31312357","citation_count":5,"is_preprint":false},{"pmid":"28658440","id":"PMC_28658440","title":"New evidences on the regulation of SF-1 expression by POD1/TCF21 in adrenocortical tumor cells.","date":"2017","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/28658440","citation_count":4,"is_preprint":false},{"pmid":"39438390","id":"PMC_39438390","title":"Targeting Mitochondrial Cholesterol Efflux via TCF21/ABCA10 Pathway to Enhance Cisplatin Efficacy in Ovarian Cancer.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39438390","citation_count":4,"is_preprint":false},{"pmid":"32382324","id":"PMC_32382324","title":"lncRNA PICART1 alleviates progression of cervical cancer by upregulating TCF21.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32382324","citation_count":4,"is_preprint":false},{"pmid":"40753125","id":"PMC_40753125","title":"Tcf21 modulates fibroblast activation and promotes cardiac fibrosis after injury via Pdgfrb signaling.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40753125","citation_count":3,"is_preprint":false},{"pmid":"35201460","id":"PMC_35201460","title":"Upregulation of TCF21 inhibits migration of adrenocortical carcinoma cells.","date":"2021","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35201460","citation_count":3,"is_preprint":false},{"pmid":"30955268","id":"PMC_30955268","title":"[Effect of TCF21 on proliferation, migration and vascular production of breast cancer cells].","date":"2019","source":"Zhonghua bing li xue za zhi = Chinese journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30955268","citation_count":3,"is_preprint":false},{"pmid":"35603952","id":"PMC_35603952","title":"N-type calcium channel v2.2 is a target of TCF21 in adrenocortical carcinomas.","date":"2022","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/35603952","citation_count":3,"is_preprint":false},{"pmid":"24758904","id":"PMC_24758904","title":"[Effects of tumor suppressor gene TCF21 on the proliferation, migration and apoptosis of A549 cells].","date":"2014","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24758904","citation_count":3,"is_preprint":false},{"pmid":"34148307","id":"PMC_34148307","title":"Studies on the Role of the Transcription Factor Tcf21 in the Transdifferentiation of Parietal Epithelial Cells into Podocyte-Like Cells.","date":"2021","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34148307","citation_count":2,"is_preprint":false},{"pmid":"38197316","id":"PMC_38197316","title":"TCF21 rs2327429 and TCF21 rs12190287 are associated with colorectal cancer in a Chinese population.","date":"2024","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38197316","citation_count":1,"is_preprint":false},{"pmid":"39326465","id":"PMC_39326465","title":"Aberrant TCF21 upregulation in adenomyosis impairs endometrial decidualization by increasing PDE4C expression.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39326465","citation_count":1,"is_preprint":false},{"pmid":"38197329","id":"PMC_38197329","title":"Transcription factor Tcf21 modulates urinary bladder size and differentiation.","date":"2024","source":"Development, growth & differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38197329","citation_count":1,"is_preprint":false},{"pmid":"40659157","id":"PMC_40659157","title":"Inhibition of ERO1A by TCF21 curbs aerobic glycolysis and enhances immune recognition in lung adenocarcinoma.","date":"2025","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/40659157","citation_count":1,"is_preprint":false},{"pmid":"39603023","id":"PMC_39603023","title":"Down-regulated BNC1 promotes glioma by inhibiting ferroptosis via TCF21/PI3K signaling pathway BNC1TCF21PI3K.","date":"2024","source":"Tissue & cell","url":"https://pubmed.ncbi.nlm.nih.gov/39603023","citation_count":1,"is_preprint":false},{"pmid":"39589156","id":"PMC_39589156","title":"Tcf21 as a founder transcription factor in specifying Foxd1 cells to the juxtaglomerular cell lineage.","date":"2024","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/39589156","citation_count":1,"is_preprint":false},{"pmid":"39211232","id":"PMC_39211232","title":"The transcription factor TCF21 is necessary for adoption of cell fates by Foxd1+ stromal progenitors during kidney development.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39211232","citation_count":1,"is_preprint":false},{"pmid":"41926244","id":"PMC_41926244","title":"Single nucleus RNA sequencing and functional in vivo studies reveal TCF21 as a protective regulator in cardiac fibrosis.","date":"2026","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/41926244","citation_count":1,"is_preprint":false},{"pmid":"41460181","id":"PMC_41460181","title":"miR-124 orchestrates epicardial-mesenchymal transformation and paracrine cardiomyocyte maturation in epicardial-specific Tcf21-PKR1 knockout mice.","date":"2026","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/41460181","citation_count":1,"is_preprint":false},{"pmid":"41786705","id":"PMC_41786705","title":"TCF21 promotes epithelial-to-mesenchymal transition and cytoskeleton reorganization in uterine development and endometriosis.","date":"2026","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41786705","citation_count":0,"is_preprint":false},{"pmid":"38585851","id":"PMC_38585851","title":"Tcf21 as a Founder Transcription Factor in Specifying Foxd1 Cells to the Juxtaglomerular Cell Lineage.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38585851","citation_count":0,"is_preprint":false},{"pmid":"41673874","id":"PMC_41673874","title":"TCF21-WNT5A axis drives metastasis of colorectal cancer via stromal-tumor cell communication.","date":"2026","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41673874","citation_count":0,"is_preprint":false},{"pmid":"41290516","id":"PMC_41290516","title":"TCF21 Downregulation Induces ERO1A Expression and Upregulates IDO1 to Trigger Immune Escape in Lung Adenocarcinoma.","date":"2025","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/41290516","citation_count":0,"is_preprint":false},{"pmid":"41360282","id":"PMC_41360282","title":"Epicardial Tcf21 facilitates cardiomyocyte dedifferentiation and heart regeneration in zebrafish.","date":"2025","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/41360282","citation_count":0,"is_preprint":false},{"pmid":"41632505","id":"PMC_41632505","title":"The transcription factor Tcf21 is necessary for adoption of cell fates by Foxd1+ stromal progenitors during kidney development.","date":"2026","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/41632505","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53793,"output_tokens":12360,"usd":0.17339,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23804,"output_tokens":6731,"usd":0.143648,"stage2_stop_reason":"end_turn"},"total_usd":0.317038,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"Tcf21 (bHLH transcription factor) is required for lineage-specific epithelial-to-mesenchymal transition (EMT) of cardiac fibroblast progenitors in the epicardium; Tcf21-null hearts fail to form cardiac fibroblasts, and lineage-traced null cells are unable to undergo EMT, establishing Tcf21 as essential for cardiac fibroblast specification prior to EMT initiation.\",\n      \"method\": \"Tcf21-null mouse genetics, tamoxifen-inducible Cre lineage tracing, histological and immunofluorescence phenotyping\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotype, lineage tracing; replicated conceptually in multiple subsequent studies\",\n      \"pmids\": [\"22573622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pod1 (Tcf21) inhibits differentiation of epicardium-derived cells (EPDCs) into smooth muscle cells in the developing heart; loss of Pod1 results in increased smooth muscle marker expression on the heart surface and a paucity of interstitial fibroblasts, with epicardial EMT relatively unaffected; Pod1 expression in EPDCs is activated by retinoic acid signaling.\",\n      \"method\": \"Pod1 knockout mouse model, immunofluorescence for smooth muscle markers, retinoic acid treatment of isolated chick EPDCs, in vivo RA inhibition experiments\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in mouse with defined cellular phenotype plus pharmacological manipulation; independently consistent with cardiac fibroblast paper\",\n      \"pmids\": [\"22687751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Tcf21 is required for proepicardial cell specification and formation of a mature epithelial epicardium in Xenopus; mass spectrometry of Tcf21 immunoprecipitates established its association with transcriptional co-repressor proteins, supporting a function for Tcf21 as a transcriptional repressor that controls proepicardial lineage determination.\",\n      \"method\": \"Tcf21 depletion in Xenopus (morpholino), mass spectrometry-based interactome, in vivo systems analysis of gene expression changes\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — MS-based co-IP identifying co-repressor interactions plus genetic depletion phenotype in a vertebrate model\",\n      \"pmids\": [\"23637334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The lncRNA TARID activates TCF21 expression by inducing promoter demethylation: TARID physically interacts with both the TCF21 promoter and GADD45A, which then recruits thymine-DNA glycosylase for base-excision-repair-mediated demethylation; this involves TET-enzyme-mediated oxidation of 5-methylcytosine to 5-hydroxymethylcytosine at the TCF21 promoter.\",\n      \"method\": \"RNA immunoprecipitation, chromatin immunoprecipitation, bisulfite sequencing, base-excision repair assays, TET enzyme inhibition\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods (RIP, ChIP, bisulfite-seq, BER assay) in one rigorous study establishing the demethylation mechanism\",\n      \"pmids\": [\"25087872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TCF21 is epigenetically silenced in lung and head and neck cancers by aberrant promoter methylation; exogenous expression of TCF21 in cells that have silenced endogenous TCF21 reduces tumor properties in vitro and in vivo, establishing a tumor suppressor function linked to its role in regulating mesenchymal-to-epithelial transition.\",\n      \"method\": \"Restriction landmark genomic scanning, methylation-specific PCR, exogenous TCF21 expression in cell lines, in vitro and xenograft tumor assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple methods (RLGS, MSP, functional rescue in vitro and in vivo); founding mechanistic study replicated widely\",\n      \"pmids\": [\"16415157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A coronary heart disease–associated SNP (rs12190287) in the TCF21 3'-UTR disrupts an miR-224 binding site; the disease-associated C allele shows faster RNA–RNA complex formation and greater miR-224 binding compared with the protective G allele, leading to allele-specific reduction of TCF21 expression; miR-224 modulates TCF21 transcriptional response to TGF-β and PDGF signaling in an allele-specific manner.\",\n      \"method\": \"3'-UTR reporter gene assays in HCASMC, kinetic in vitro RNA-RNA binding assays, Pb2+/RNase T1 RNA probing, allelic imbalance analysis, miR-224 modulation experiments\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro biochemical RNA binding plus functional reporter assays plus allelic imbalance in patient tissue, multiple orthogonal methods\",\n      \"pmids\": [\"24676100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The lead CHD-associated polymorphism rs12190287 disrupts an atypical AP-1 element in a TCF21 cis-regulatory enhancer, as demonstrated by allele-specific transcriptional regulation, transcription factor binding, and chromatin organization; this element also mediates signaling through PDGFR-β and WT1 pathways to regulate TCF21 expression.\",\n      \"method\": \"Luciferase reporter allele-specific assays, EMSA/TF binding assays, chromatin accessibility analysis, PDGFR-β and WT1 pathway perturbation experiments\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (reporter assay, TF binding, chromatin organization) in one study\",\n      \"pmids\": [\"23874238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TCF21 promotes proliferation and migration and inhibits SMC lineage marker expression in human coronary artery SMC (HCASMC); vascular wall cells expressing Tcf21 migrate into atherosclerotic vascular lesions and contribute to the fibrous cap, where they activate SMC marker and growth factor receptor gene expression; RNA-Seq after siRNA knockdown identified downstream pathways related to vascular disease, cellular movement, and growth/proliferation.\",\n      \"method\": \"siRNA knockdown + RNA-Seq in HCASMC, in vitro proliferation/migration assays, reporter gene studies, immunolocalization, Cre-based lineage tracing in ApoE-/- and Ldlr-/- mice\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (RNA-Seq, in vitro functional assays, in vivo lineage tracing), two mouse models\",\n      \"pmids\": [\"26020946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF21 antagonizes the MYOCD-SRF pathway to suppress SMC differentiation through multiple mechanisms: (1) TCF21 suppresses MYOCD and SRF at RNA and protein level; (2) ChIP-seq shows TCF21 binding colocalizes with SRF binding sites including at a novel SRF gene enhancer and MYOCD gene promoter; (3) TCF21 directly inhibits transcription at these sites via reporter assays; (4) TCF21 physically interacts with MYOCD (protein co-immunoprecipitation), blocking MYOCD-SRF association.\",\n      \"method\": \"ChIP-seq, siRNA/overexpression in HCASMC, luciferase reporter transfection assays, protein co-immunoprecipitation, in vitro genome editing of SRF CArG box, mouse in vivo mutation of orthologous enhancer\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (ChIP-seq, co-IP, reporter assay, genome editing in vitro and in vivo) in one rigorous study\",\n      \"pmids\": [\"31815603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SMC-specific knockout of TCF21 in mice markedly inhibits SMC phenotypic modulation in atherosclerosis, leading to fewer fibromyocytes and fewer fibrous cap cells within lesions; single-cell RNA-seq established that modulated SMCs transform into fibroblast-like 'fibromyocytes' (not macrophages), and TCF21 expression strongly associates with this process in human coronary arteries.\",\n      \"method\": \"SMC-specific TCF21 knockout mouse, single-cell RNA sequencing of mouse and human atherosclerotic lesions, immunohistochemistry\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with defined phenotype plus human single-cell transcriptomic validation; high-impact replicated study\",\n      \"pmids\": [\"31359001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TCF21 and SMAD3 promote opposing transcriptional programs in HCASMC: SMAD3 promotes SMC differentiation marker expression while inhibiting proliferation, opposing TCF21's pro-dedifferentiation activity; at colocalized DNA binding sites, SMAD3 and TCF21 binding are inversely correlated, with TCF21 locally blocking chromatin accessibility at SMAD3 binding sites; TCF21 directly inhibits SMAD3 activation of gene expression in reporter assays.\",\n      \"method\": \"RNA-Seq, ChIP-Seq for SMAD3 and TCF21 in HCASMC, chromatin accessibility (ATAC-seq), luciferase reporter transfection assays, siRNA knockdown\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (ChIP-seq, ATAC-seq, reporter assay, RNA-seq) in one study\",\n      \"pmids\": [\"30307970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ChIP-seq in HCASMC identified the canonical TCF21 DNA binding sequence as CAGCTG; TCF21 binding sites significantly overlap AP-1 (JUN/JUND) binding loci in HCASMC; TCF21 target genes are enriched for processes including 'growth factor binding,' 'matrix interaction,' and 'smooth muscle contraction.'\",\n      \"method\": \"ChIP-seq with TCF21, JUN, and JUND antibodies in HCASMC; motif analysis; eQTL overlap analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq with multiple transcription factors; canonical motif independently confirmed in additional studies\",\n      \"pmids\": [\"26020271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TCF21 binds the promoter of the melanoma metastasis-suppressing gene KISS1 and enhances its gene expression through interaction with E12 (TCF3 isoform) and TCF12; loss of TCF21 expression causes loss of KISS1 expression through loss of direct TCF21 occupancy at the KISS1 promoter; TCF21 overexpression inhibits motility of melanoma cells.\",\n      \"method\": \"Chromatin immunoprecipitation at KISS1 promoter, co-immunoprecipitation with E12/TCF12, siRNA knockdown, cell motility assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and co-IP establish direct binding and protein interaction; single lab, multiple methods\",\n      \"pmids\": [\"21771727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SRY directly binds to the Tcf21 promoter at SRY/SOX9 response elements and activates TCF21 gene expression; mutagenesis of SRY/SOX9 response elements in the Tcf21 promoter eliminates SRY-driven activation; SRY was found to associate with the Tcf21 promoter in vivo during fetal rat testis development; TCF21 promotes in vitro sex reversal of embryonic ovarian cells to induce precursor Sertoli cell differentiation.\",\n      \"method\": \"Promoter reporter assays with mutagenesis, ChIP of SRY at Tcf21 promoter in fetal rat testis, embryonic ovarian cell culture sex-reversal assay, transcriptome analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reporter + mutagenesis + in vivo ChIP + functional sex-reversal assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"21637323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ChIP-chip analysis identified 121 direct downstream TCF21 binding targets in Sertoli cells; one key bHLH target is scleraxis (Scx); SRY and TCF21 induce initial stages of Sertoli cell differentiation, while SCX induces later stages, establishing a cascade SRY→TCF21→SCX that promotes Sertoli cell fate.\",\n      \"method\": \"ChIP-chip comparative hybridization for TCF21 targets, embryonic ovarian gonadal cell culture sex-reversal assay with Sry, Tcf21, and Scx transfections, transferrin gene expression as Sertoli marker\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-chip genome-wide target identification plus functional differentiation assay; single lab\",\n      \"pmids\": [\"23034159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TCF21 is sumoylated by SUMO1 at lysine residue K24; mutation of K24 to arginine completely abolishes sumoylation; sumoylation stabilizes TCF21 protein without affecting subcellular localization; sumoylation enhances TCF21 interaction with HDAC1/2 (without affecting TCF21-ERα interaction); sumoylated TCF21 shows enhanced recruitment of HDAC1/2 to the pS2 promoter and enhanced repression of ERα transcriptional activity; SENP1 reverses TCF21 sumoylation.\",\n      \"method\": \"Co-immunoprecipitation for SUMO1-TCF21 and HDAC1/2-TCF21, site-directed mutagenesis (K24R), protein half-life assay with SUMOylation inhibitor, subcellular localization assay, ChIP at pS2 promoter, luciferase reporter assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple co-IP and mutagenesis experiments; single lab with orthogonal methods\",\n      \"pmids\": [\"27028856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF21 is required for visceral adipose stem cell (ASC)-specific expression of IL-6; TCF21 also promotes MMP-dependent collagen degradation and type IV collagen deposition through regulation of MMP2, MMP13, TIMP1, and COL4A1 in visceral ASCs; the MMP2 and COL4A1 regulatory effects are IL-6-independent.\",\n      \"method\": \"siRNA-mediated Tcf21 knockdown and lentiviral TCF21 overexpression in mouse ASCs, qRT-PCR, ELISA for IL-6, zymography for MMP activity, collagen assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function experiments with multiple downstream readouts; single lab\",\n      \"pmids\": [\"29540474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"POD-1/TCF21 overexpression reduces SHP mRNA and protein levels by binding to E-box sequences in the SHP promoter (demonstrated by ChIP), indirectly affecting LRH-1 regulation and increasing Cyclin E1 expression; this is mechanistically distinct from TCF21's regulation of SF-1.\",\n      \"method\": \"ChIP assay at SHP promoter, qRT-PCR, Western blot for SHP, LRH-1, and Cyclin E1 in hepatocarcinoma and adrenocortical tumor cells with POD-1 overexpression\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus protein expression analysis; single lab, multiple cell types\",\n      \"pmids\": [\"26421305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"POD-1/TCF21 overexpression significantly decreases endogenous SF-1 mRNA and protein in adrenal fasciculata/reticularis (F/R) cells, and also decreases the SF-1 target StAR; this effect is cell-zone-specific (not observed in glomerulosa cells), corroborating direct TCF21-mediated repression of SF-1 in normal adrenocortical cells.\",\n      \"method\": \"Primary culture of rat adrenal G and F/R cells, pCMVMycPod-1 transfection, qRT-PCR, Western blot for SF-1, StAR, CYP11B2\",\n      \"journal\": \"Brazilian journal of medical and biological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with multiple downstream molecular readouts; single lab\",\n      \"pmids\": [\"26421867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF21 directly promotes LPL gene transcription by binding to the E-box motif in the LPL promoter, as demonstrated by ChIP and luciferase assays; TCF21 knockdown and overexpression attenuate and promote preadipocyte differentiation respectively, with changes in C/EBPα, LPL, and A-FABP expression.\",\n      \"method\": \"Chromatin immunoprecipitation assay, luciferase reporter assay, siRNA knockdown, TCF21 overexpression in chicken preadipocytes, lipid droplet accumulation quantification\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase assay establish direct binding at LPL promoter; single lab\",\n      \"pmids\": [\"31065241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SUMOylation of TCF21 is increased in endometriotic tissues and is enhanced by estrogen; SUMOylation stabilizes TCF21 protein (shown by protein half-life assay with ginkgolic acid) and increases its interaction with USF2 (co-immunoprecipitation); SUMOylated TCF21 shows increased binding activity of USF2 to the SF-1 and ERβ promoters; TCF21/USF2 heterodimer binds to SF-1 and ERβ promoters to activate their expression.\",\n      \"method\": \"Co-immunoprecipitation, protein half-life assay with SUMOylation inhibitor, ChIP at SF-1 and ERβ promoters, estrogen treatment experiments in endometriotic stromal cells\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, half-life assay, and ChIP are orthogonal; single lab\",\n      \"pmids\": [\"33693540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ChIP-seq in adrenocortical carcinoma NCI-H295R cells overexpressing TCF21 identified CACNA1B (encoding N-type calcium channel Cav2.2) as a direct TCF21 target; TCF21 negatively regulates CACNA1B/Cav2.2 expression, suggesting a mechanism of steroidogenesis control in addition to SF-1 inhibition.\",\n      \"method\": \"ChIP-seq in NCI-H295R cells overexpressing TCF21, validation by qRT-PCR and Western blot for CACNA1B\",\n      \"journal\": \"Neoplasma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with validation; single lab\",\n      \"pmids\": [\"35603952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Tcf21 directly binds gene loci including COL1A1, COL3A1, IL6, and PDGFRB (by ChIP-seq); Tcf21 promotes cardiac fibroblast activation and fibrosis through upregulation of extracellular matrix genes and the Pdgfrb-Erk pathway; Tcf21-knockout fibroblasts show severely suppressed Pdgfrb-Erk signaling; inducible Tcf21 KO mice are resistant to cardiac fibrosis induced by isoproterenol or metabolic overload.\",\n      \"method\": \"ChIP-seq in Tcf21-knockout vs WT cardiac fibroblasts, in vitro fibroblast culture from KO embryos, inducible Tcf21 KO mouse models (isoproterenol and streptozotocin/HFD), gene expression analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq, multiple KO mouse models with disease phenotype, in vitro mechanistic confirmation; single lab but orthogonal methods\",\n      \"pmids\": [\"40753125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF21 inhibits anti-angiogenic activity in cholangiocarcinoma by targeting PI3K/Akt and ERK1/2 signaling; ectopic TCF21 expression in CCA cells reduces VEGFA and PDGF-BB expression/secretion (shown by immunohistochemistry and ELISA) and conditioned medium from TCF21-overexpressing cells reduces endothelial cell viability, migration, and tube formation; PI3K/Akt and ERK1/2 pathway inhibition mediates these effects.\",\n      \"method\": \"Lentiviral TCF21 overexpression in CCA cell lines, conditioned medium endothelial cell assays (viability, migration, tube formation), xenograft growth, immunohistochemistry, ELISA for VEGFA/PDGF-BB, Western blot for signaling pathway proteins\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro functional assays with molecular readouts; single lab, multiple methods\",\n      \"pmids\": [\"30920845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TCF21 interacts with p53 signaling as a transcriptional target of p53 in response to hypoxia in uterine endometrial carcinoma cells; TCF21 interferes with the MAPK pathway by reducing phosphorylated ERK1 (MAPK1), and a specific domain of TCF21 responsible for interaction with MEK was identified by molecular docking and mutagenesis.\",\n      \"method\": \"TCF21 overexpression in UCEC cells, hypoxia treatment of wild-type vs p53-deficient cells, molecular docking and mutagenesis of TCF21 domain, Western blot for phospho-ERK, in vitro proliferation and invasion assays, in vivo xenograft\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mutagenesis identified binding domain but molecular docking is computational; interaction with MEK not confirmed by co-IP; single lab\",\n      \"pmids\": [\"29608330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TCF21 overexpression in FAP-high cancer-associated fibroblasts (CAFs) in ovarian cancer decreases their ability to promote invasion, chemoresistance, and in vivo tumor growth, acting as a master regulator of CAF state; TCF21 is specifically expressed in FAP-low CAFs.\",\n      \"method\": \"TCF21 overexpression in FAP-high CAFs, co-culture invasion assays, in vivo tumor growth assays, flow cytometry for CD49e/FAP markers\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional overexpression with in vitro and in vivo readouts; single lab\",\n      \"pmids\": [\"32434219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF21 lineage cells constitute the lung lipofibroblast population; after E15.5, Tcf21 progenitor cells exclusively become lipofibroblasts and interstitial fibroblasts; overexpression of Tcf21 in primary neonatal lung fibroblasts increases intracellular neutral lipids, suggesting Tcf21 regulates lipofibroblast function.\",\n      \"method\": \"Tcf21 inducible Cre lineage tracing at multiple embryonic time points, lipid staining (neutral lipid quantification), Tcf21 overexpression in neonatal lung fibroblasts\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lineage tracing plus functional overexpression with lipid readout; single lab\",\n      \"pmids\": [\"30675802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DNMT3a binds the TCF21 promoter resulting in TCF21 hypermethylation in hepatic stellate cells (HSCs); TCF21 downstream binding protein hnRNPA1 inhibits the NF-κB signaling pathway to accelerate hepatic fibrosis reversal; the DNMT3a-TCF21-hnRNPA1 axis regulates HSC activation.\",\n      \"method\": \"ChIP for DNMT3a at TCF21 promoter, bisulfite sequencing, co-immunoprecipitation for TCF21-hnRNPA1 interaction, NF-κB pathway inhibition assays in HSCs\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and co-IP establish molecular interactions; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37268177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TCF21 loss in epicardium-derived cells causes increased myofibroblast differentiation, whereas TCF21 overexpression suppresses TGF-β signaling and myofibroblast differentiation; lncRNA-TARID (enriched in mesenchymal stem cell EVs) upregulates Tcf21 expression in epicardium-derived cells, and TARID-laden lipid nanoparticles improve cardiac function in mouse and porcine myocardial infarction models.\",\n      \"method\": \"Gain- and loss-of-function experiments in epicardium-derived cells, TGF-β signaling pathway analysis (Western blot), intrapericardial EV injection in mouse MI model, lipid nanoparticle delivery of lncRNA-TARID in mouse and porcine MI models\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss/gain-of-function with molecular pathway readout, in vivo models in two species; single lab\",\n      \"pmids\": [\"36916305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tcf21 inhibits adipogenesis at least partially by accentuating Dlk1 expression; loss of Tcf21 in visceral adipose Tcf21 lineage cells (Tcf21 LCs) promotes adipogenesis and developmental progress, leading to improved metabolic health in diet-induced obesity; multiomics (scRNA-seq + chromatin accessibility) defined the gene-regulatory network governing Tcf21 LC activities.\",\n      \"method\": \"Tcf21 conditional knockout mice, scRNA-seq, ATAC-seq, gene-regulatory network analysis, metabolic phenotyping under HFD\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with multiomics and functional metabolic readout; single lab\",\n      \"pmids\": [\"36857185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ChIP-seq in parietal epithelial cells (PECs) transfected with Tcf21-GFP identified a genome-wide Tcf21 binding site consensus as CAGCTG (E-box motif CANNTG); Tcf21 expression in PECs downregulates PEC-specific markers (caveolin-1, β-catenin, Pax2) and the transcription factor YY1; co-expression of YY1 with Tcf21 rescues Tcf21-induced multinucleation/budding/micronuclei and tetraploidy; Tcf21 target genes include cell cycle regulators (Mdm2, Cdc45, Cyclin D1, Cyclin D2) and microtubule stability genes.\",\n      \"method\": \"ChIP-seq in Tcf21-GFP-transfected PECs, motif analysis, qRT-PCR and Western blot for target genes/proteins, co-expression rescue experiments, flow cytometry for ploidy\",\n      \"journal\": \"Cellular physiology and biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with functional validation of binding motif and target genes; single lab\",\n      \"pmids\": [\"34148307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TCF21 directly interacts with HHIP protein (co-immunoprecipitation); inhibition of TCF21 or HHIP individually promotes liver cancer cell proliferation and metastasis; knockdown of TCF21 or HHIP counteracts the protective effects of miR-25-3p inhibitor on cell proliferation and metastasis.\",\n      \"method\": \"Co-immunoprecipitation for TCF21-HHIP interaction, luciferase reporter for miR-25-3p targeting, siRNA knockdown of TCF21/HHIP, CCK-8/transwell/wound-healing assays, xenograft\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP for TCF21-HHIP interaction; functional consequence not fully dissected from TCF21 alone\",\n      \"pmids\": [\"32525231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TCF21 directly binds the ABCA10 promoter (confirmed by dual-luciferase reporter and ChIP assay) to activate ABCA10 expression; TCF21 overexpression increases ABCA10-mediated mitochondrial cholesterol efflux in DDP-resistant ovarian cancer cells, sensitizing them to cisplatin; knockdown of ABCA10 reverses TCF21's ability to enhance cisplatin sensitivity.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP assay for TCF21 at ABCA10 promoter, lentiviral ABCA10 overexpression/knockdown and TCF21 overexpression in DDP-resistant OV cell lines, mitochondrial cholesterol measurement, cholesterol efflux assay, apoptosis assay\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay establish direct binding; functional rescue with multiple molecular readouts; single lab\",\n      \"pmids\": [\"39438390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TCF21 directly activates PDE4C expression by binding to its promoter (confirmed by ChIP-seq and dual-luciferase reporter assay); TCF21 overexpression in endometrial stromal cells suppresses intracellular cAMP levels by upregulating PDE4C and also suppresses FOXO1 expression, thereby impairing decidualization.\",\n      \"method\": \"RNA-seq after TCF21 overexpression in HESCs, ChIP-seq and ChIP-qPCR for TCF21 at PDE4C promoter, dual-luciferase reporter assay, cAMP ELISA, FOXO1/decidual marker qRT-PCR/Western blot\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and reporter assay confirm direct TCF21-PDE4C binding; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"39326465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TCF21 transcriptionally represses ERO1A expression (confirmed by dual-luciferase/ChIP assay); TCF21-mediated ERO1A repression reduces IDO1 expression and PD-L1 levels, thereby limiting immune evasion in lung adenocarcinoma cells; TCF21 overexpression inhibits LUAD cell migration/invasion and enhances CD8+ T cell cytotoxicity.\",\n      \"method\": \"Dual-luciferase assay and ChIP for TCF21-ERO1A binding, gene knockdown/overexpression experiments, Seahorse metabolic analysis, flow cytometry for CD8+ T cell activation, transwell migration/invasion assays, LUAD mouse models\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay establish direct binding; functional rescue experiments; single lab\",\n      \"pmids\": [\"40659157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"TCF21 directly activates LIMK2 transcription (ChIP-seq and epigenomic data in patient-derived ectopic stromal cells); TCF21-activated LIMK2-cofilin signaling promotes actin-cytoskeleton reorganization, increased cell invasion and adhesion in endometriotic stromal cells; uterine-specific Tcf21 knockout in mice dysregulates EMT of endometrium; TCF21 overexpression via AAV-Pgr-Tcf21 increases endometriosis incidence in mice, which is mitigated by LIMK inhibitor LIMKi 3.\",\n      \"method\": \"ChIP-seq in patient-derived ectopic stromal cells, uterine-specific Tcf21 conditional KO mice, AAV-Pgr-Tcf21 mouse model, LIMK inhibitor treatment, actin cytoskeleton imaging, invasion/adhesion assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq, multiple in vivo mouse models (KO and OE), pharmacological rescue, and functional cellular assays; single lab but orthogonal methods\",\n      \"pmids\": [\"41786705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TCF21 directly promotes chicken preadipocyte differentiation by binding to the E-box motif in the HTR2A promoter (genome-wide ChIP-seq, ChIP-qPCR, and luciferase reporter assay); pharmacological activation or inhibition of HTR2A respectively promotes or attenuates preadipocyte differentiation; HTR2A inhibition impairs TCF21-promoted adipogenesis.\",\n      \"method\": \"ChIP-seq and RNA-seq in chicken differentiated preadipocytes, ChIP-qPCR and luciferase reporter validation of HTR2A as direct target, pharmacological HTR2A modulation, oil red-O staining\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq + reporter assay establish direct binding; functional rescue with pharmacology; single lab\",\n      \"pmids\": [\"34872001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Loss of Tcf21 in cardiac fibroblasts causes increased myofibroblast-like gene expression and differentiation; AAV-mediated cardiac fibroblast-specific TCF21 overexpression in vivo exerts an anti-fibrotic effect and improves cardiac remodelling in a mouse model; snRNA-seq identified a disease-specific fibroblast subpopulation in human aortic stenosis where TCF21 is a key regulator.\",\n      \"method\": \"snRNA-seq of human fibrotic and non-failing hearts, cardiac fibroblast-specific AAV-knockdown and AAV-overexpression in vivo in mice, in vitro cardiac fibroblast loss/gain-of-function, immunohistochemistry\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo AAV-based KD and OE with cardiac phenotype plus human snRNA-seq validation; multiple orthogonal approaches\",\n      \"pmids\": [\"41926244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TCF21 in tumor pericytes increases perivascular ECM stiffness, collagen rearrangement, and basement membrane degradation; loss of integrin α5 in TCF21-high pericytes inhibits the FAK/PI3K/AKT/DNMT1 axis to impair TCF21 DNA hypermethylation; pericyte-conditional Tcf21 knockout mitigates perivascular ECM remodelling and colorectal cancer liver metastasis.\",\n      \"method\": \"scRNA-seq, pericyte-conditional Tcf21 KO mice (CRC model), ChIP-seq and bisulfite-seq, atomic force microscopy for ECM stiffness, second-harmonic generation microscopy, integrin α5 pathway inhibition studies\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO mice plus ChIP-seq and pathway inhibition; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"36805487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TCF21 (Tcf21) directly regulates the Slug promoter by occupying E-box sequences; Tcf21-Slug balance defines distinct migratory modalities (proliferative/passive cooperative cell migration, active CCM, and EMT) in high-grade serous ovarian cancer cells; phenotypic transitions following drug exposure ensue from occupancy of Slug promoter E-boxes by Tcf21.\",\n      \"method\": \"ChIP at Slug promoter E-boxes, gene manipulation (overexpression/knockdown) of Tcf21 and Slug, live imaging of cell migration, flow cytometry\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP at target promoter plus functional gene manipulation with live imaging; single lab\",\n      \"pmids\": [\"31241128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Tcf21 is required for specification of Foxd1+ stromal progenitors to the juxtaglomerular (JG) cell lineage during early kidney development (E12); Tcf21 inactivation in Foxd1+ cells (but not in Ren1+ cells) results in fewer renin-positive areas and altered renal arterial morphology; pseudotime trajectory analysis shows Tcf21 expression is highest in early metanephric mesenchyme and declines as cells mature into renin-expressing JG cells.\",\n      \"method\": \"Foxd1;Tcf21 conditional KO and Ren1;Tcf21 conditional KO mouse models, immunostaining, in situ hybridization, scRNA-seq, scATAC-seq, pseudotime trajectory analysis\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in two cell-type-specific models with multiomics (scRNA-seq + scATAC-seq) plus histological validation; peer-reviewed with preprint version also available\",\n      \"pmids\": [\"39589156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of Tcf21 in Foxd1+ stromal progenitors results in depletion of multiple stromal subpopulations (medullary/perivascular, collecting duct-associated, proliferating, and nephrogenic zone-associated stroma) and emergence of a novel Emcn-expressing stromal population with profibrotic transcriptional programs; Tcf21 loss leads to architectural disruption, interstitial fibrosis, and impaired renal function in adult mice.\",\n      \"method\": \"scRNA-seq on E14.5 Foxd1-lineage cells from Tcf21-cKO and control kidneys, scATAC-seq, immunostaining, bulk RNA-seq at E18.5, histological analysis at 2 months\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with scRNA-seq, scATAC-seq and longitudinal histology; multiple orthogonal approaches\",\n      \"pmids\": [\"41632505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Loss of tcf21 in zebrafish epicardial cells reduces the presence of dedifferentiated cardiomyocytes in the injury area and impairs heart regeneration, establishing that epicardial Tcf21 is required for cardiomyocyte dedifferentiation during cardiac regeneration.\",\n      \"method\": \"Conditional tcf21 flox allele with 4-OHT-inducible CreERT2 in adult zebrafish, ventricular resection heart injury model, quantification of dedifferentiated cardiomyocytes, histological assessment of regeneration\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic deletion in zebrafish with defined regeneration phenotype; single lab\",\n      \"pmids\": [\"41360282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TCF21 regulates miR-224-mediated allelic imbalance at rs12190287 in HCASMC: higher TCF21 expression is anti-correlated with miR-224 levels, and miR-224 modulates TCF21 transcriptional response to TGF-β and PDGF in an allele-specific manner, indicating bimodal regulatory complexity at this CAD locus (previously also shown: rs12190287 disrupts AP-1 binding; see PMID 23874238).\",\n      \"method\": \"miR-224 and TCF21 expression correlation in HCASMC; miR-224 overexpression and inhibition experiments with TGF-β/PDGF treatment, allele-specific reporter assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional experiments in primary HCASMC with allele-specific readouts; single lab, builds on prior AP-1 study\",\n      \"pmids\": [\"24676100\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TCF21 is a class II bHLH transcription factor that binds E-box sequences (canonical CAGCTG) in target gene promoters/enhancers to act primarily as a transcriptional repressor of smooth muscle cell (SMC) differentiation—by directly interacting with and blocking the MYOCD-SRF pathway and by opposing SMAD3 activity—while promoting SMC phenotypic modulation toward a fibroblast-like state during atherosclerosis; it is essential for cardiac fibroblast specification from epicardial progenitors (requiring EMT), for Foxd1+ kidney stromal progenitor fate determination, and for Sertoli cell differentiation downstream of SRY; its activity is post-translationally regulated by SUMO1-mediated sumoylation (at K24, reversed by SENP1) which stabilizes the protein and enhances HDAC1/2 recruitment; its expression is epigenetically controlled by promoter methylation/demethylation (via the TARID lncRNA–GADD45A–TET–BER pathway) and post-transcriptionally by miR-224 (allele-specifically at rs12190287); in cancer contexts TCF21 functions as a tumor suppressor by activating KISS1, repressing PI3K/AKT and ERK signaling, promoting mesenchymal-to-epithelial reversion, and directly activating ABCA10-mediated mitochondrial cholesterol efflux, while in cardiac and endometrial fibrosis it directly binds and regulates ECM gene loci (COL1A1, COL3A1) and activates LIMK2-cofilin signaling to drive cytoskeletal reorganization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TCF21 is a class II basic helix-loop-helix transcription factor that controls mesenchymal cell-fate determination, fibroblast specification, and phenotypic plasticity across cardiovascular, renal, gonadal, and tumor contexts, binding the canonical E-box CAGCTG and frequently overlapping AP-1 (JUN/JUND) loci in target enhancers [#11, #30]. In the developing heart it is essential for specifying cardiac fibroblast progenitors and their epithelial-to-mesenchymal transition from the epicardium, while restraining differentiation of epicardium-derived cells toward smooth muscle [#0, #1]. In vascular smooth muscle, TCF21 drives phenotypic modulation toward a fibroblast-like 'fibromyocyte' state that populates the atherosclerotic fibrous cap, acting as a transcriptional repressor of the SMC differentiation program: it suppresses and physically binds MYOCD to block MYOCD-SRF complex formation, and it antagonizes SMAD3 by locally restricting chromatin accessibility at shared binding sites [#7, #8, #9, #10]. Beyond the vasculature, TCF21 acts downstream of SRY through SRY/SOX9 promoter elements to initiate Sertoli cell differentiation via a SRY→TCF21→SCX cascade [#13, #14], and is required for specification of Foxd1+ renal stromal progenitors, whose loss causes stromal depletion, emergence of profibrotic populations, and interstitial fibrosis [#40, #41]. TCF21 expression is set epigenetically: the lncRNA TARID recruits GADD45A and the TET/base-excision-repair machinery to demethylate the TCF21 promoter [#3], a circuit silenced by aberrant promoter methylation in cancer where TCF21 acts as a tumor suppressor [#4]. A coronary-disease-associated polymorphism (rs12190287) tunes TCF21 levels through both disruption of an enhancer AP-1 element and allele-specific miR-224 binding in its 3'-UTR [#5, #6]. TCF21 protein is stabilized and rendered a more potent repressor by SUMO1 sumoylation at K24, which enhances HDAC1/2 recruitment and is reversed by SENP1 [#15]. Its direct transcriptional outputs are context-specific, including activation of the metastasis suppressor KISS1 [#12], repression of MYOCD/SRF and SMAD3 targets in SMCs [#8, #10], direct regulation of ECM and PDGFRB-ERK genes (COL1A1, COL3A1, PDGFRB) driving cardiac fibroblast activation [#22, #37], and activation of LIMK2-cofilin signaling promoting cytoskeletal reorganization and invasion in endometriosis [#35].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established TCF21 as a tumor suppressor silenced by promoter methylation, defining the first disease-relevant mechanism and linking its loss to mesenchymal-to-epithelial transition control.\",\n      \"evidence\": \"Restriction landmark genomic scanning, methylation-specific PCR, and functional rescue in cell lines and xenografts in lung and head/neck cancer\",\n      \"pmids\": [\"16415157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct transcriptional targets mediating suppression\", \"Mechanism of MET reversion not defined at the gene level\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified TCF21 as a direct activator of the metastasis suppressor KISS1 and a partner of E12/TCF12, providing an early molecular handle on its tumor-suppressive transcriptional output.\",\n      \"evidence\": \"ChIP at KISS1 promoter, co-IP with E12/TCF12, and motility assays in melanoma cells\",\n      \"pmids\": [\"21771727\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Whether KISS1 activation generalizes beyond melanoma not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed TCF21 downstream of SRY in male sex determination, showing SRY directly activates the Tcf21 promoter to drive Sertoli cell differentiation.\",\n      \"evidence\": \"Promoter reporter mutagenesis, in vivo ChIP of SRY in fetal rat testis, and ovarian cell sex-reversal assays\",\n      \"pmids\": [\"21637323\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TCF21 direct targets in Sertoli cells not yet mapped at this stage\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined TCF21 as essential for cardiac fibroblast specification and EMT from epicardial progenitors while restraining SMC differentiation, establishing its developmental fibroblast-fate role.\",\n      \"evidence\": \"Tcf21-null and Pod1 knockout mouse genetics, lineage tracing, and retinoic acid manipulation\",\n      \"pmids\": [\"22573622\", \"22687751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in epicardial EMT not identified\", \"Co-repressor partners not yet defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapped genome-wide TCF21 targets in Sertoli cells and defined a SRY→TCF21→SCX differentiation cascade, extending the gonadal program downstream.\",\n      \"evidence\": \"ChIP-chip target identification and Sry/Tcf21/Scx sex-reversal transfection assays\",\n      \"pmids\": [\"23034159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect target distinction limited by ChIP-chip resolution\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided biochemical evidence that TCF21 functions as a transcriptional repressor by associating with co-repressor complexes during proepicardial lineage determination.\",\n      \"evidence\": \"Mass-spectrometry interactome of Tcf21 immunoprecipitates plus morpholino depletion in Xenopus\",\n      \"pmids\": [\"23637334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific co-repressor subunits and target loci not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected the coronary-disease GWAS signal to TCF21 regulation, showing rs12190287 disrupts an enhancer AP-1 element controlling allele-specific expression downstream of PDGFR-β and WT1.\",\n      \"evidence\": \"Allele-specific luciferase reporters, TF-binding/EMSA, chromatin accessibility, and pathway perturbation in vascular cells\",\n      \"pmids\": [\"23874238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal in vivo demonstration of the variant effect on disease not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined the TARID lncRNA–GADD45A–TET–base-excision-repair circuit that activates TCF21 by promoter demethylation, explaining how TCF21 silencing is reversed.\",\n      \"evidence\": \"RIP, ChIP, bisulfite-seq, BER assays, and TET inhibition in one integrated study\",\n      \"pmids\": [\"25087872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals controlling TARID expression not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established a second, post-transcriptional layer of the CAD locus: rs12190287 alters a 3'-UTR miR-224 site, tuning TCF21 response to TGF-β and PDGF allele-specifically.\",\n      \"evidence\": \"3'-UTR reporters, kinetic RNA-RNA binding assays, RNA probing, and allelic imbalance in HCASMC\",\n      \"pmids\": [\"24676100\", \"23874238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of enhancer vs 3'-UTR mechanisms to disease risk not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the canonical TCF21 DNA-binding motif (CAGCTG) genome-wide and showed extensive co-binding with AP-1, framing how TCF21 engages SMC enhancers.\",\n      \"evidence\": \"ChIP-seq with TCF21/JUN/JUND antibodies and motif/eQTL analysis in HCASMC\",\n      \"pmids\": [\"26020271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AP-1 co-binding is cooperative or antagonistic not resolved here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated functionally that TCF21 promotes SMC proliferation/migration, suppresses SMC markers, and contributes vascular cells to the atherosclerotic fibrous cap.\",\n      \"evidence\": \"siRNA-RNA-Seq, in vitro functional assays, and lineage tracing in ApoE-/- and Ldlr-/- mice\",\n      \"pmids\": [\"26020946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct repression mechanism of SMC genes not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended TCF21 repressor function to steroidogenic and metabolic loci, showing E-box-dependent repression of SHP and SF-1.\",\n      \"evidence\": \"ChIP at SHP promoter and gain-of-function expression analysis in adrenocortical and hepatocarcinoma cells\",\n      \"pmids\": [\"26421305\", \"26421867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct vs indirect SF-1 repression not fully separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified SUMO1 sumoylation at K24 (reversed by SENP1) as a post-translational switch that stabilizes TCF21 and enhances HDAC1/2-dependent repression.\",\n      \"evidence\": \"Co-IP, K24R mutagenesis, half-life and ChIP/reporter assays at the pS2 promoter\",\n      \"pmids\": [\"27028856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"SUMO ligase and physiological signals triggering sumoylation not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed TCF21 directly controls EMT/migration modality via E-box occupancy at the Slug promoter, linking it to cancer cell phenotypic transitions.\",\n      \"evidence\": \"ChIP at Slug E-boxes with gene manipulation and live migration imaging in ovarian cancer cells\",\n      \"pmids\": [\"31241128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Whether Slug regulation is activating or repressive context-dependent\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the TCF21–SMAD3 antagonism in SMCs, showing TCF21 locally blocks chromatin accessibility at SMAD3 sites to oppose SMC differentiation.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, RNA-seq and reporter assays in HCASMC\",\n      \"pmids\": [\"30307970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which TCF21 reduces accessibility not biochemically defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established the central mechanism of SMC phenotypic modulation: TCF21 antagonizes MYOCD-SRF transcriptionally and by physically binding MYOCD, and SMC-specific deletion blocks fibromyocyte formation in atherosclerosis.\",\n      \"evidence\": \"ChIP-seq, co-IP, reporter and genome editing assays plus SMC-specific KO and single-cell RNA-seq of mouse and human lesions\",\n      \"pmids\": [\"31815603\", \"31359001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether fibromyocyte fate is protective or detrimental in human disease not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Broadened TCF21 function into adipose/lung mesenchymal and fibrotic biology, regulating IL-6, MMP/collagen genes, LPL, and lipofibroblast identity.\",\n      \"evidence\": \"Loss/gain-of-function with qRT-PCR, zymography, ChIP/luciferase, and lineage tracing in adipose, lung, and preadipocyte models\",\n      \"pmids\": [\"29540474\", \"30675802\", \"31065241\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single labs per tissue\", \"Cross-tissue conservation of these targets unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed TCF21 suppresses pro-angiogenic and pro-survival signaling (VEGFA/PDGF-BB, PI3K/Akt, ERK1/2) consistent with its tumor-suppressor role.\",\n      \"evidence\": \"Ectopic expression, conditioned-medium endothelial assays, and signaling Westerns in cholangiocarcinoma\",\n      \"pmids\": [\"30920845\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct transcriptional targets mediating signaling suppression not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined TCF21 as a master regulator of fibroblast/pericyte/stromal cell states across cancer and metabolic contexts, including CAF state, adipogenesis via Dlk1/HTR2A, and parietal epithelial cell ploidy via YY1.\",\n      \"evidence\": \"Overexpression and conditional KO with multiomics (scRNA-seq, ATAC-seq), ChIP-seq, and functional rescue across ovarian CAF, adipose, and renal PEC systems\",\n      \"pmids\": [\"32434219\", \"36857185\", \"34148307\", \"34872001\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-specific direct targets only partially overlapping\", \"Single labs per system\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed that sumoylation-dependent TCF21–USF2 heterodimers can act as activators (of SF-1 and ER-β) in estrogen-driven endometriosis, showing TCF21 can switch from repressor to activator depending on partner.\",\n      \"evidence\": \"Co-IP, half-life and ChIP assays at SF-1/ER-β promoters in endometriotic stromal cells\",\n      \"pmids\": [\"33693540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Determinants selecting repressor vs activator complexes unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended TCF21 regulation and function to fibrosis-relevant tissues, including DNMT3a-mediated promoter methylation in hepatic stellate cells and suppression of TGF-β-driven myofibroblast differentiation rescued by TARID delivery.\",\n      \"evidence\": \"ChIP, bisulfite-seq, co-IP (hnRNPA1) in HSCs and gain/loss-of-function with EV/lipid-nanoparticle TARID delivery in mouse and porcine MI models\",\n      \"pmids\": [\"37268177\", \"36916305\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single labs\", \"Whether TARID therapy effects are fully TCF21-dependent not isolated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified additional direct TCF21 targets linking it to cholesterol efflux, decidualization, renal progenitor specification, and tumor immune evasion.\",\n      \"evidence\": \"ChIP/ChIP-seq and reporter assays (ABCA10, PDE4C, ERO1A) plus conditional KO with multiomics in kidney (Foxd1 lineage)\",\n      \"pmids\": [\"39438390\", \"39326465\", \"39589156\", \"40659157\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each target validated in a single context\", \"Generality of cholesterol/immune outputs unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established TCF21 as a direct, context-determinant regulator of fibrosis: it activates ECM/PDGFRB-ERK and LIMK2-cofilin programs to drive fibrosis in some tissues while restraining myofibroblast conversion in others, with in vivo anti-fibrotic effects of cardiac TCF21 overexpression.\",\n      \"evidence\": \"ChIP-seq, multiple inducible/conditional KO and AAV overexpression mouse models, pharmacological LIMK inhibition, and human snRNA-seq\",\n      \"pmids\": [\"40753125\", \"41786705\", \"41926244\", \"41360282\", \"41632505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why TCF21 is pro-fibrotic in some fibroblasts but anti-fibrotic in others is unresolved\", \"Direct chromatin determinants of the opposite outcomes not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TCF21 selects between transcriptional repression (MYOCD/SRF, SMAD3, ERO1A) and activation (KISS1, ABCA10, LIMK2) at distinct loci, and what cofactor/PTM context dictates pro- versus anti-fibrotic outcomes, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model of repressor-vs-activator switching\", \"Structural basis of partner selection (E12/TCF12, USF2, MYOCD, HDAC1/2) not determined\", \"Determinants of tissue-specific fibrosis outcome unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 8, 10, 11, 12, 13, 22, 30, 32, 33, 34, 35]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [11, 30, 8, 32, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8, 11, 15, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [8, 10, 11, 13, 22, 30, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 13, 40, 41]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 9, 7, 22, 35]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [16, 22, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MYOCD\", \"SMAD3\", \"HDAC1\", \"HDAC2\", \"USF2\", \"TCF12\", \"SUMO1\", \"hnRNPA1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}